Statistical Methodology and Applications in Biostatistics
Kimura R, Nomura S, Nagashima K, Sato Y. Comparison between asymptotic and re-randomisation tests
under non-proportional hazards in a randomised controlled trial using the minimisation method.
BMC Medical Research Methodology 2024;24(1):166. DOI: 10.1186/s12874-024-02295-2.
Gosho M, Ohigashi T, Nagashima K, Ito Y, Maruo K. Bias in odds ratios from logistic regression
methods with sparse data set.
Journal of Epidemiology
2023;33(6):265–275. DOI: 10.2188/jea.JE20210089.
Noma H, Nagashima K, Kato S, Teramukai S, Furukawa TA. Flexible random-effects distribution models
for meta-analysis. Journal of Epidemiology
2022;32(10):441–448. DOI: 10.2188/jea.JE20200376. [arXiv:2003.04598]
Hamaguchi Y, Noma H, Nagashima K, Yamada T, Furukawa TA. Frequentist performances of Bayesian
prediction intervals for random-effects meta-analysis.
Biometrical Journal
2021;63(2):394–405. DOI: 10.1002/bimj.201900351. [arXiv:1907.00345]
Nagashima K, Noma H, Sato Y, Gosho M. Sample size calculations for single-arm survival studies using
transformations of the Kaplan–Meier estimator.
Pharmaceutical Statistics
2021;20(3):499–511. DOI: 10.1002/pst.2090. [arXiv:2012.03355]
Nagashima K, Noma H, Furukawa TA. Prediction intervals for random-effects meta-analysis: a
confidence distribution approach.
Statistical Methods in Medical Research
2019;28(6):1689–1702.
DOI:
10.1177/0962280218773520. [arXiv:1804.01054][Software]
Noma H, Nagashima K, Maruo K, Gosho M, Furukawa TA. Bartlett-type corrections and bootstrap
adjustments of likelihood-based inference methods for network meta-analysis.
Statistics in Medicine
2018;37(7):1178–1190. DOI: 10.1002/sim.7578.
Gosho M, Sato Y, Nagashima K, Takahashi S. Trends in study design and the statistical methods
employed in a leading general medicine journal.
Journal of Clinical Pharmacy and Therapeutics
2018;43(1):36–44. DOI: 10.1111/jcpt.12605.
Sato Y, Gosho M, Nagashima K, Takahashi S, Ware JH, Laird NM. Statistical methods in the
Journal — an update.
New England Journal of Medicine
2017;376(11):1086–1087. DOI: 10.1056/NEJMc1616211.
(Correspondence)
HOT
Nagashima K, Sato Y. Information criteria for Firth's penalized partial likelihood approach in Cox
regression models. Statistics in Medicine
2017;36(21):3422–3436. DOI: 10.1002/sim.7368. [Postprint]
Noma H, Nagashima K. A note on the Mantel–Haenszel estimators when the common effect
assumptions are violated.
Epidemiologic Methods
2016;5(1):19–35. DOI: 10.1515/em-2015-0004.
Nagashima K, Sato Y, Noma H, Hamada C. An efficient and robust method for analyzing population
pharmacokinetic data in genome-wide pharmacogenomic studies: a generalized estimating equation
approach. Statistics in Medicine
2013;32(27):4838–4858. DOI: 10.1002/sim.5895. [arXiv:1805.05017]
Gosho M, Nagashima K, Sato Y. Study designs and statistical analyses for biomarker research.
Sensors
2012;12(7):8966–8986.
DOI: 10.3390/s120708966. (Review)
Nagashima K, Sato Y, Hamada C. A modified maximum contrast method for unequal sample sizes in
pharmacogenomic studies.
Statistical Applications in Genetics and Molecular
Biology
2011;10(1):Article 41.
DOI: 10.2202/1544-6115.1560.
[arXiv:2012.03475][Software]
Sato Y, Laird NM, Nagashima K, Kato R, Hamano T, Yafune A, Kaniwa N, Saito Y, Sugiyama E, Kim S-R,
Furuse J, Ishii H, Ueno H, Okusaka T, Saijo N, Sawada J-i, Yoshida T. A new statistical screening
approach for finding pharmacokinetics-related genes in genome-wide studies.
The Pharmacogenomics Journal
2009;9(2):137–146. DOI: 10.1038/tpj.2008.17.
Medical Researches
Matsuyama E, Miyata J, Terai H, Miyazaki N, Iwasaki T, Nagashima K, Watase M, Sunata K, Namkoong H,
Asakura T, Masaki K, Chubachi S, Ohgino K, Kawada I, Minami K, Hagiwara R, Ueda S, Yoshiyama T, Kokuto
H, Kusumoto T, Oashi A, Miyawaki M, Saito F, Tani T, Ishioka K, Takahashi S, Nakamura M, Ishii M, Sato
Y, Fukunaga K. Chronic obstructive pulmonary disease, asthma, and mechanical ventilation are risk
factors for dyspnea in patients with long COVID: a Japanese nationwide cohort study.
Respiratory Investigation
2024;62(6):1094–1101.
DOI: 10.1016/j.resinv.2024.09.009.
Yamaguchi T, Kumagai K, Yagi S, Nomura T, Nagashima K, Watanabe M, Makuuchi R, Kawakami K, Matsushima
T, Kadowaki S, Haruta S, Cho H, Kakihara N, Otsuka S, Yamada T, Imai Y, Fukunaga H, Boku N. Efficacy
of chemotherapy for patients with gastric cancer with early recurrence during or after adjuvant
chemotherapy with S-1 alone: A multicenter retrospective study.
Scientific Reports
2024;14(1):21854.
DOI: 10.1038/s41598-024-72423-x.
Aotsuka Y, Misawa S, Suichi T, Shibuya K, Nakamura K, Kano H, Otani R, Morooka M, Ogushi M, Nagashima
K, Sato Y, Kuriyama N, Kuwabara S. Multifocal motor neuropathy in Japan: A nationwide survey on
prevalence, clinical profiles, and treatment.
Muscle & Nerve
2024;70(5):1027–1033.
DOI: 10.1002/mus.28251.
Yamaguchi R*, Oda T*, Nagashima K. Comparison of the diagnostic accuracy of shear wave elastography
with transient elastography in adult nonalcoholic fatty liver disease: a systematic review and network
meta-analysis of diagnostic test accuracy.
Abdominal Radiology 2024.
In press.
DOI: 10.1007/s00261-024-04546-8.
(*equally contributed)
Katsumata Y, Muramoto Y, Ishida N, Takemura R, Nagashima K, Ikoma T, Kawamatsu N, Araki M, Goda A,
Okawara H, Sawada T, Ichihara YK, Hattori O, Yamaoka K, Seki Y, Ryuzaki T, Ikura H, Nakashima D,
Nagura T, Nakamura M, Sato K, Shiraishi Y. Sweat lactate sensor for detecting anaerobic threshold in
heart failure: a prospective clinical trial (LacS-001).
Scientific Reports
2024;14(1):18985.
DOI: 10.1038/s41598-024-70001-9.
Fujita M, Nagashima K, Uno T, Hashimoto H, Suzuki K, Kasai T, Yamaguchi K, Onouchi Y, Sato D, Fujisawa
T, Hata A. Impact of the COVID-19 pandemic on hypofractionated radiotherapy use for breast cancer in
Japan: a nationwide study.
Advances in Radiation Oncology 2024;9(8):101555.
DOI: 10.1016/j.adro.2024.101555.
Hishikawa A, Nishimura ES, Yoshimoto N, Nakamichi R, Hama EY, Ito W, Maruki T, Nagashima K,
Shimizu-Hirota R, Takaishi H, Itoh H, Hayashi K. Predicting exacerbation of renal function by DNA
methylation clock and DNA damage of urinary shedding cells: a pilot study.
Scientific Reports
2024;14(1):11530.
DOI: 10.1038/s41598-024-62405-4.
Yoshitake M, Sugiyama A, Shimohata T, Araki N, Suzuki M, Shibuya K, Nagashima K, Hattori N, Kuwabara
S. Delivering the diagnosis of multiple system atrophy: A multicenter survey on Japanese neurologists'
perspectives.
BMC Neurology
2024;24(1):137–146.
DOI: 10.1186/s12883-024-03666-4.
Inoue M, Ogasawara S, Kobayashi K, Okubo T, Itokawa N, Obu M, Fujimoto K, Unozawa H, Yumita S,
Fujiwara K, Nakagawa M, Kanzaki H, Koroki K, Kiyono S, Nakamura M, Kanogawa N, Kondo T, Nakamoto S,
Nagashima K, Itobayashi E, Atsukawa M, Koma Y, Azemoto R, Kato N. Assessment of macrovascular invasion
in advanced hepatocellular carcinoma: clinical implications and treatment outcomes with systemic
therapy.
Liver Cancer 2024.
In press.
DOI: 10.1159/000539380.
Fujita M, Nagashima K, Shimazu M, Suzuki M, Tauchi I, Sakuma M, Yamamoto S, Hanaoka H, Shozu M,
Tsuruoka N, Kasai T, Hata A. Effectiveness of self-sampling human papillomavirus test on pre-cancer
detection and screening uptake in Japan: The ACCESS randomized controlled trial.
International Journal of Cancer 2024;155(5):905–915.
DOI: 10.1002/ijc.34970.
Uchida S, Uno S, Kondo M, Uwamino Y, Namkoong H, Nishimura T, Misawa K, Kashimura S, Yamato K,
Ishizaka T, Nagashima K, Kitagawa Y, Hasegawa N. Factors affecting motivation for receiving a booster
dose of the COVID-19 vaccine among Japanese university students and staff: A cross-sectional
questionnaire survey.
Scientific Reports 2024;14(1):8009.
DOI: 10.1038/s41598-024-58603-9.
Miyazaki N, Iwasaki T, Sakai H, Watanuki R, Tanizawa Y, Cai Z, Kawaguchi T, Tsurutani J, Nagashima K.
Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor
receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis.
Current Medical Research and Opinion 2024;40(5):827–837.
DOI: 10.1080/03007995.2024.2332436.
Fujita M, Fujisawa T, Suzuki K, Nagashima K, Kasai T, Hashimoto H, Yamaguchi K, Onouchi Y, Sato D,
Hata A. Impact of the coronavirus disease 2019 pandemic on primary and metastatic lung cancer
treatments in Japan: A nationwide study using an interrupted time series analysis.
Cancer Epidemiology 2024;90:102549. DOI: 10.1016/j.canep.2024.102549.
Fujita M, Yamaguchi K, Nagashima K, Suzuki K, Kasai T, Hashimoto H, Onouchi Y, Sato D, Fujisawa T,
Hata A. Impact of the COVID-19 pandemic on gastric surgery in Japan: A nationwide study using
interrupted time-series analyses.
Journal of Gastroenterology and Hepatology
2024;39(7):1277–1284.
DOI: 10.1111/jgh.16533.
Okada M, Ishida N, Kanzaki S, Kawada I, Nagashima K, Terai H, Hiruma G, Namkoong H, Asakura T, Masaki
K, Ohgino K, Miyata J, Chubachi S, Kodama N, Maeda S, Sakamoto S, Okamoto M, Nagasaki Y, Umeda A,
Miyagawa K, Shimada H, Minami K, Hagiwara R, Ishii M, Sato Y, Fukunaga K. Upper respiratory symptoms
as long COVID revealed through a cohort study of patients with COVID-19.
OTO Open 2024;8(1):e120. DOI: 10.1002/oto2.120.
Tsutsui K, Ukita S, Kondo M, Toshima G, Miyazaki N, Nagashima K, Ohmura M, Tsuchihashi S, Tsuji Y,
Katoh M, Aida N, Kobayashi Y, Ohtsu Y, Fujita Y, Tanaka S, Watanabe H, Naruse Y, Iizuka I, Kato H,
Mashimo Y, Senbonmatsu T. Synergistic effect of motivation for the elderly and support for going out
II; measures to induce elderly men to go out.
Geriatrics 2024;9(1):21. DOI: 10.3390/geriatrics9010021.
Okui J*, Nagashima K*, Matsuda S*, Sato Y, Okamura A, Kawakubo H, Muto M, Kakeji Y, Kono K, Takeuchi
H, Watanabe M, Doki Y, Bamba T, Fukuda T, Fujiwara H, Sato S, Noma K, Miyata H, Fujita T, Kitagawa Y.
Recurrence-free survival as a surrogate endpoint for overall survival after neoadjuvant chemotherapy
and surgery for oesophageal squamous cell carcinoma.
British Journal of Surgery 2024;111(2):znae038. DOI: 10.1093/bjs/znae038.
(*equally contributed)
Aotsuka Y, Misawa S, Suichi T, Shibuya K, Nakamura K, Kano H, Otani R, Marie M, Ogushi M, Nagashima K,
Sato Y, Kuriyama N, Kuwabara S. Prevalence and clinical profiles of anti-myelin-associated
glycoprotein neuropathy in Japan: A nationwide survey study of 133 patients.
European Journal of Neurology 2024;31(5):e16249.
DOI: 10.1111/ene.16249.
Yamada Y, Nagashima K, Azuma M, Masutani M, Ichikawa H, Iwasa S, Takahashi N, Hirano H, Kanato K,
Machida N, Kinoshita T, Hata H, Kawakami H, Takahari D, Boku N, Kurokawa Y, Terashima M, Yoshikawa T,
Sekine S, Hiraoka N. Predictive and prognostic value of excision repair cross-complementing group 1 in
patients with advanced gastric cancer.
BJC Reports 2024;
2: 18. DOI: 10.1038/s44276-024-00046-w.
Kashiro A, Kobayashi M, Oh T, Miyamoto M, Atsumi J, Nagashima K, Takeuchi K, Nara S, Hijioka S,
Morizane C, Kikuchi S, Kato S, Kato K, Ochiai H, Obata D, Shizume Y, Konishi H, Nomura Y, Matsuyama K,
Xie C, Wong C, Huang Y, Jung G, Srivastava S, Kutsumi H, Honda K. Clinical development of a blood
biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer.
Journal of Gastroenterology 2024;
59(3): 263–278.
DOI: 10.1007/s00535-023-02072-w.
Aotsuka Y, Misawa S, Suichi T, Shibuya K, Nakamura K, Kano H, Otani R, Morooka M, Ogushi M, Nagashima
K, Sato Y, Kuriyama N, Kuwabara S. Prevalence, clinical profiles, and prognosis of CIDP in Japanese
nationwide survey: analyses of 1257 diagnosis-confirmed patients. Neurology 2024;102(6):e209130.
DOI: 10.1212/WNL.0000000000209130.
Kishimoto T, Kinoshita S, Kitazawa M, Hishimoto A, Asami T, Suda A, Bun S, Kikuchi T, Sado M, Takamiya
A, Mimura M, Sato Y, Takemura R, Nagashima K, Nakamae T, Abe Y, Kanazawa T, Kawabata Y, Tomita H, Abe
K, Hongo S, Kimura H, Sato A, Kida H, Sakuma K, Funayama M, Sugiyama N, Hino K, Amagai T, Takamiya M,
Kodama H, Goto K, Fujiwara S, Kaiya H, Nagao K, on behalf of the J-PROTECT collaborators. Live two-way
video versus face-to-face treatment for depression, anxiety, and obsessive-compulsive disorder: A
24-week randomized controlled trial.
Psychiatry and Clinical Neurosciences 2024;
78(4): 220–228.
DOI: 10.1111/pcn.13618.
Shimozaki K, Nakayama I, Takahari D, Nagashima K, Yoshino K, Fukuda K, Fukuoka S, Osumi H, Ogura M,
Wakatsuki T, Ooki A, Shinozaki E, Chin K, Yamaguchi K. Efficacy and safety of trastuzumab deruxtecan
and nivolumab as third- or later-line treatment for HER2-positive advanced gastric cancer: a
single-institution retrospective study.
Journal of Gastric Cancer
2023;23(4):e41. DOI: 10.5230/jgc.2023.23.e41.
Nomura K, Kitagawa K, Tsuji M, Iida M, Aoki M, Miyauchi K, Hirayama J, Nagashima K, Takebayashi T,
Tsutsumi A. The quantity and quality of scientific evidence about the health of working women in
occupational health of Japan: A scoping review.
Journal of Occupational Health
2023;65(1):e12427. DOI: 10.1002/1348-9585.12427.
Terai H, Ishii M, Takemura R, Namkoong H, Shimamoto K, Masaki K, Tanosaki T, Chubachi S, Matsuyama E,
Hayashi R, Shimada T, Shigematsu L, Ito F, Kaji M, Takaoka H, Kurihara M, Nakagawara K, Tomiyasu S,
Sasahara K, Saito A, Otake S, Azegawa S, Okada M, Fukushima T, Morita A, Tanaka H, Sunata K, Asaoka M,
Nishie M, Shinozaki T, Ebisudani T, Akiyama Y, Mitsuishi A, Nakayama S, Ogawa T, Sakurai K, Irie M,
Yagi K, Ohgino K, Miyata J, Kabata H, Ikemura S, Kamata H, Yasuda H, Kawada I, Kimura R, Kondo M,
Iwasaki T, Ishida N, Hiruma G, Miyazaki N, Ishibashi Y, Harada S, Fujita T, Ito D, Bun S, Tabuchi H,
Kanzaki S, Shimizu E, Fukuda K, Yamagami J, Kobayashi K, Hirano T, Inoue T, Haraguchi M, Kagyo J,
Shiomi T, Lee H, Sugihara K, Omori N, Sayama K, Otsuka K, Miyao N, Odani T, Watase M, Mochimaru T,
Satomi R, Oyamada Y, Masuzawa K, Asakura T, Nakayama S, Suzuki Y, Baba R, Okamori S, Arai D, Nakachi
I, Kuwahara N, Fujiwara A, Okada T, Ishiguro T, Isono T, Mashimo S, Makino Y, Kaido T, Minematsu N,
Ueda S, Minami K, Hagiwara R, Manabe T, Fukui T, Funatsu Y, Koh H, Yoshiyama T, Kokuto H, Kusumoto T,
Oashi A, Miyawaki M, Saito F, Tani T, Ishioka K, Takahashi S, Nakamura M, Harada N, Sasano H, Goto A,
Kusaka Y, Ohba T, Nakano Y, Nishio K, Nakajima Y, Suzuki S, Yoshida S, Tateno H, Kodama N, Maeda S,
Sakamoto S, Okamoto M, Nagasaki Y, Umeda A, Miyagawa K, Shimada H, Hagimura K, Nagashima K, Sato T,
Sato Y, Hasegawa N, Takebayashi T, Nakahara J, Mimura M, Ogawa K, Shimmura S, Negishi K, Tsubota K,
Amagai M, Goto R, Ibuka Y, Kitagawa Y, Kanai T, Fukunaga K. Comprehensive analysis of long COVID in a
Japanese nationwide prospective cohort study.
Respiratory Investigation 2023;
61(6): 802–814. DOI: 10.1016/j.resinv.2023.08.008.
[Preprint].
Hashimoto T, Takayanagi D, Yonemaru J, Naka T, Nagashima K, Machida E, Kohno T, Yatabe Y, Kanemitsu Y,
Hamamoto R, Takashima A, Shiraishi K, Sekine S. A comprehensive appraisal of HER2 heterogeneity in
HER2-amplified and HER2-low colorectal cancer.
British Journal of Cancer
2023;129(7):1176–1183. DOI: 10.1038/s41416-023-02382-z.
Takahashi N, Hara H, Nagashima K, Hirata K, Masuishi T, Matsumoto T, Kawakami H, Yamazaki K, Hironaka
S, Boku N, Muro K. Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab
(RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or
esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
BMC Cancer 2023;
23(1): 726. DOI: 10.1186/s12885-023-11199-1.
Fujita M, Nagashima K, Shimazu M, Suzuki M, Tauchi I, Sakuma M, Yamamoto S, Hanaoka H, Shozu M,
Tsuruoka N, Kasai T, Hata A. Acceptability of self-sampling human papillomavirus test for cervical
cancer screening in Japan: A questionnaire survey in the ACCESS trial.
PLoS ONE 2023;
18(6): e0286909. DOI: 10.1371/journal.pone.0286909.
Fujita M, Yamaguchi K, Nagashima K, Suzuki K, Kasai T, Hashimoto H, Onouchi Y, Sato D, Fujisawa T,
Hata A. Changes in colorectal cancer treatment during the COVID-19 pandemic in Japan: interrupted
time-series analysis using the National Database of Japan.
Cancer Epidemiology 2023;
85: 102391. DOI: 10.1016/j.canep.2023.102391.
Fujita M, Hashimoto H, Nagashima K, Suzuki K, Kasai T, Yamaguchi K, Onouchi Y, Sato D, Fujisawa T,
Hata A. Impact of coronavirus disease 2019 pandemic on breast cancer surgery using the National
Database of Japan. Scientific Reports 2023;
13(1): 4977. DOI: 10.1038/s41598-023-32317-w.
Takahashi R, Uchiyama K, Washida N, Shibagaki K, Yanai A, Nakayama T, Nagashima K, Sato Y, Kanda T,
Itoh H. Mean annual intradialytic blood pressure decline and cardiovascular events in Japanese
patients on maintenance hemodialysis.
Hypertension Research 2023;
46(6): 1536–1546.
DOI: 10.1038/s41440-023-01228-8.
Uwamino Y*, Nagashima K*, Yoshifuji A, Suga S, Nagao M, Fujisawa T, Ryuzaki M, Takemoto Y, Namkoong
H, Wakui M, Matsushita H, Hasegawa N, Sato Y, Murata M. Estimating immunity with mathematical models
for SARS-CoV-2 after COVID-19 vaccination.
npj Vaccines 2023;
8(1): 33. DOI: 10.1038/s41541-023-00626-w.
(*equally contributed)
Kadono T, Iwasa S, Nagashima K, Oshima K, Yamamoto S, Hirano H, Okita N, Shoji H, Honma Y, Takashima
A, Kato K, Ushijima T, Boku N. Progression patterns and site-specific responses in advanced gastric
cancer patients treated with nivolumab.
Cancer Medicine
2023; 12(8): 9322–9331.
DOI: 10.1002/cam4.5689.
Nakamura M, Ogawa R, Fujimori J, Uzawa A, Sato Y, Nagashima K, Kuriyama N, Kuwabara S, Nakashima I.
Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein
antibody-associated disease in a nationwide survey.
Multiple Sclerosis Journal
2023;29(4–5): 530–539. DOI: 10.1177/13524585231156736.
Matsumura T, Ebigbo A, Römmele C, Ikematsu H, Ishigami H, Suzuki T, Harada H, Yada T, Takatori Y,
Takeuchi M, Okimoto K, Akizue N, Maruoka D, Kitagawa Y, Minamide T, Iwaki T, Amano Y, Matsusaka K,
Nagashima K, Maehata T, Yahagi N, Messmann H, Kato N. Diagnostic value of adding magnifying
chromoendoscopy to magnifying narrow-band imaging endoscopy for colorectal polyps.
Clinical Gastroenterology and Hepatology
2023; 21(10): 2551–2559.e2. DOI: 10.1016/j.cgh.2023.01.028.
Kubo A, Masugi Y, Hase T, Nagashima K, Kawai Y, Takizawa M, Hishiki T, Shiota M, Wakui M, Kitagawa Y,
Kabe Y, Sakamoto M, Yachie A, Hayashida T, Suemats M. Polysulfide serves as a hallmark of desmoplastic
reaction to differentially diagnose ductal carcinoma in situ and invasive breast cancer by SERS
imaging. Antioxidants 2023;
12(2): 240. DOI: 10.3390/antiox12020240.
Kojima D, Washida N, Uchiyama K, Hama EY, Nagasaka T, Kusahana E, Nakayama T, Nagashima K, Sato Y,
Morimoto K, Kanda T, Itoh H. The body mass index change is associated with death or hemodialysis
transfer in Japanese patients initiating peritoneal dialysis.
Renal Failure 2023;
45(1):2163904. DOI: 10.1080/0886022X.2022.2163904.
Yamaguchi Y, Takashima A, Nagashima K, Kumagai K, Yamada T, Terashima M, Yabusaki H, Nishikawa K,
Tanabe K, Yunome G, Kawachi Y, Yamada T, Fukagawa T, Kinoshita T, Watanabe M, Ishiyama K, Inoue K,
Boku N. Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV
gastric cancer with synchronous oligo metastasis: a multicenter retrospective study.
Gastric Cancer
2023;26(2):307–316.
DOI: 10.1007/s10120-023-01363-8.
Fujita M, Nagashima K, Suzuki K, Kasai T, Hashimoto H, Yamaguchi K, Onouchi Y, Sato D, Fujisawa T,
Hata A. Changes in the number of cancer diagnosis practices due to the COVID-19 pandemic:
interrupted time-series analysis using the National Database of Japan.
Journal of Cancer Research and Clinical Oncology
2023;149(9):6023–6033. DOI: 10.1007/s00432-022-04557-2.
Numasaki M, Ito K, Takagi K, Nagashima K, Notsuda H, Ogino H, Ando R, Tomioka Y, Suzuki T, Okada Y,
Nishioka Y, Unno M. Diverse and divergent functions of IL-32β and IL-32γ isoforms in the
regulation of malignant pleural mesothelioma cell growth and the production of VEGF-A and CXCL8.
Cellular Immunology
2023;383:104652. DOI: 10.1016/j.cellimm.2022.104652.
Imamura S, Inagaki T, Abe M, Terada J, Kawasaki T, Nagashima K, Tatsumi K, Suzuki T. Impaired dynamic
response of oxygen saturation during the 6-min walk test is associated with mortality in chronic
fibrosing interstitial pneumonia.
Respiratory Care
2023;68(3):356–365.
DOI: 10.4187/respcare.10231
Aoki M, Kadowaki S, Takahashi N, Suzuki T, Oshima K, Ando T, Yamamoto Y, Kawakami K, Kito Y,
Matsumoto T, Shimozaki K, Miyazaki Y, Yamaguchi T, Nagase M, Tamura T, Amanuma Y, Esaki T, Miura Y,
Akiyoshi K, Baba E, Makiyama A, Negoro Y, Nakashima K, Sugimoto N, Nagashima K, Shoji H, Boku N.
Pattern of disease progression during third-line or later chemotherapy with nivolumab associated
with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan.
Gastric Cancer
2023;26(1):132–144. DOI: 10.1007/s10120-022-01349-y.
Tamura NT, Shikimoto R, Nagashima K, Sato Y, Nakagawa A, Irie S, Iwashita S, Mimura M, Fujisawa D.
Group multi-component programme based on cognitive behavioural therapy and positive psychology for
family caregivers of people with dementia: a randomised controlled study (3C study).
Psychogeriatrics
2023;23(1):141–156. DOI: 10.1111/psyg.12919.
Ota Y, Nomura K, Fujita N, Suzuki T, Kamatsuka M, Sakata N, Nagashima K, Hirayama J, Fujita N, Shiga
K, Oyama N, Terada Y. Influence of LINE-assisted provision of information about human papillomavirus
and cervical cancer prevention on HPV vaccine intention: A randomized controlled trial.
Vaccines
2022;10(12):2005. DOI: 10.3390/vaccines10122005.
Yamada Y, Kobayashi H, Nagashima K, Sugihara K. Real impact of oxaliplatin in adjuvant chemotherapy
for patients with stage III colon cancer based on the Multi-Institutional Registry of Large Bowel
Cancer in Japan. Global Health & Medicine
2022;4(5):259–267. DOI: 10.35772/ghm.2022.01048.
Suzuki T, Ota Y, Sakata N, Fujita N, Kamatsuka M, Nagashima K, Hirayama J, Terada Y, Nomura K. HPV
vaccine intention among university students during suspension of active recommendation in Japan.
Human Vaccines & Immunotherapeutics
2022;18(6):2116900. DOI: 10.1080/21645515.2022.2116900.
Fujita M, Nagashima K, Shimazu M, Suzuki M, Tauchi I, Sakuma M, Yamamoto S, Hanaoka H, Shozu M,
Tsuruoka N, Kasai T, Hata A. Implementation of a self-sampling HPV test for non-responders to
cervical cancer screening in Japan: secondary analysis of the ACCESS trial.
Scientific Reports
2022;12(1):14531. DOI: 10.1038/s41598-022-18800-w.
Hirata K, Sato T, Nakamura M, Kato K, Hirano H, Kumekawa Y, Hino K, Kawakami K, Kito Y, Matsumoto T,
Kawakami T, Komoda M, Nagashima K, Sato Y, Yamazaki K, Hironaka S, Takaishi H, Hamamoto Y, Muro K.
WJOG13219G: the efficacy and safety of FOLFOXIRI or doublet plus anti-VEGF therapy in previously
untreated BRAFV600E mutant metastatic colorectal
cancer: a multi-institutional registry-based study (BRACELET study).
Clinical Colorectal Cancer
2022;21(4):339–346. DOI: 10.1016/j.clcc.2022.08.002.
Eriguchi T, Takeda A, Nemoto T, Tsurugai Y, Sanuki N, Tateishi Y, Kibe Y, Akiba T, Inoue M,
Nagashima K, Horita N. Relationship between dose prescription methods and local control rate in
stereotactic body radiotherapy for early-stage non-small cell lung cancer: systematic review and
meta-analysis. Cancers
2022;14(15):3815. DOI: 10.3390/cancers14153815.
Mashimo Y, Tsuchihashi S, Tsutsui K, Arai T, Tsuji Y, Numai T, Kameda K, Nishizawa K, Kobati M,
Tanaka S, Watanabe H, Naruse Y, Ohmura M, Ishida N, Iwasaki T, Hiruma G, Miyazaki N, Takemura R,
Nagashima K, Sato Y, Ohtsu Y, Nakano T, Aida N, Iizuka I, Kato H, Kobayashi Y, Senbonmatsu T.
Synergistic effect of motivation for the elderly and support for going out.
Journal of Personalized Medicine
2022;12(8):1257. DOI: 10.3390/jpm12081257.
Ito T, Takashima A, Yamazaki K, Yukami H, Uetake H, Tsuda M, Suto T, Moriwaki T, Sugimoto N, Ojima
H, Takii Y, Yasui H, Esaki T, Tsuji A, Goto M, Saruta M, Otsu S, Shinozaki K, Fujiwara T, Tamura T,
Baba E, Shiozawa M, Denda T, Ueno H, Nagashima K, Shimada Y. Primary tumor location as a predictor
of survival in patients with RAS wild-type colorectal cancer
who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational
study by the Japanese Society for Cancer of the Colon and Rectum.
International Journal of Clinical Oncology
2022;27(9):1450–1458. DOI: 10.1007/s10147-022-02208-7.
Hashimoto T, Takayanagi D, Yonemaru J, Naka T, Nagashima K, Yatabe Y, Shida D, Hamamoto R, Kleeman
SO, Leedham SJ, Maughan T, Takashima A, Shiraishi K, Sekine S. Clinicopathological and molecular
characteristics of RSPO fusion-positive colorectal cancer.
British Journal of Cancer
2022;127(6):1043–1050. DOI: 10.1038/s41416-022-01880-w.
Watanabe K, Shibuya K, Misawa S, Nagashima K, Suzuki Y-i, Suichi T, Kojima Y, Nakamura K, Kano H,
Prado M, Uzawaa A, Kuwabara S. Impaired neuromuscular transmission in facial muscles of amyotrophic
lateral sclerosis: A single-fiber electromyography study.
Neurology and Clinical Neuroscience
2022;10(2):78–82. DOI: 10.1111/ncn3.12580.
Fujita M, Shimazu M, Nagashima K, Suzuki M, Tauchi I, Sakuma M, Yamamoto S, Shozu M, Hanaoka H,
Tsuruoka N, Kasai T, Hata A. Study protocol of the ACCESS trial: A randomized trial to evaluate the
effectiveness of human papillomavirus testing by self-sampling in cervical cancer screening uptake
and precancer detection. BMJ Open
2022;12(2):e049803. DOI: 10.1136/bmjopen-2021-049803.
Noro R, Honda K, Nagashima K, Motoi N, Kunugi S, Matsubayashi J, Takeuchi S, Shiraishi H, Okano T,
Kashiro A, Meng X, Yoshida Y, Watanabe S-i, Usuda J, Inoue T, Wilber H, Ikeda N, Seike M, Gemma A,
Kubota K. Alpha-actinin-4 (ACTN4) gene amplification is a
predictive biomarker for adjuvant chemotherapy with UFT in stage I lung adenocarcinomas.
Cancer Science
2022;113(3):1002–1009. DOI: 10.1111/cas.15228.
Kobayashi K, Ogasawara S, Takahashi A, Seko Y, Unozawa H, Sato R, Watanabe S, Moriguchi M, Morimoto
N, Tsuchiya S, Iwai K, Inoue M, Ogawa K, Ishino T, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Koroki
K, Nakamura M, Kanogawa N, Kiyono S, Kondo T, Saito T, Nakagawa R, Suzuki E, Ooka Y, Nakamoto S,
Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Nagashima K, Kato J, Isoda N, Aramaki T, Itoh Y,
Kato N. Evolution of survival impact of molecular target agents in patients with advanced
hepatocellular carcinoma. Liver Cancer
2022;11(1):48–60. DOI: 10.1159/000519868.
Hasegawa T, Seo T, Kubota Y, Sudo T, Yokota K, Miyazaki N, Muranaka A, Hirano S, Yamauchi A,
Nagashima K, Iyo M, Sakai I. Reliability and validity of the Japanese version of the 4A's Test for
delirium screening in the elderly patient.
Asian Journal of Psychiatry
2022;67:102918. DOI: 10.1016/j.ajp.2021.102918.
Felix K*, Honda K*, Nagashima K, Kashiro A, Takeuchi K, Kobayashi T, Hinterkopf S, Gaida MM, Dang H,
Brindl N, Kaiser J, Büchler MW, Strobel O. Non-invasive risk stratification of IPMN with
malignant potential by serum apolipoprotein-A2-isoforms.
International Journal of Cancer
2022;150(5):881–894. DOI: 10.1002/ijc.33875.
(*equally contributed)
Yamamoto S, Nagashima K, Kawakami T, Mitani S, Komoda M, Tsuji Y, Izawa N, Kawakami K, Yamamoto Y,
Makiyama A, Yamazaki K, Masuishi T, Esaki T, Nakajima TE, Okuda H, Moriwaki T, Boku N. Second-line
chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab
for patients with metastatic colorectal cancer.
BMC Cancer
2021;21(1):1159. DOI: 10.1186/s12885-021-08890-6.
Shoji H, Takahari D, Hara H, Nagashima K, Adachi J, Boku N. A phase I study of pevonedistat plus
CapeOX in patients with advanced gastric cancer refractory to platinum (NCCH-1811).
Future Science OA
2021;7(7):FSO721. DOI: 10.2144/fsoa-2021-0023.
Honda K, Hishiki T, Yamamoto S, Yamamoto T, Miura N, Kubo A, Itoh M, Chen W-Y, Takano M, Yoshikawa
T, Kasamatsu T, Sonoda S, Yoshizawa H, Nakamura S, Itai Y, Shiota M, Koike D, Naya M, Hayakawa N,
Naito Y, Matsuura T, Iwaisako K, Masui T, Uemoto S, Nagashima K, Hashimoto Y, Sakuma T, Matsubara O,
Huang W, Ida T, Akaike T, Masugi Y, Sakamoto M, Kato T, Ino Y, Yoshida H, Tsuda H, Hiraoka N, Kabe
Y, Suematsu M. On-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits
patients with ovarian cancer to predict post-operative chemosensitivity.
Redox Biology
2021;41:101926. DOI: 10.1016/j.redox.2021.101926.
Iwase M, Matsuura Y, Kuniyoshi K, Suzuki T, Nagashima K, Ohtori S. Biomechanical evaluation of
opponenplasty for low median palsy: a cadaver study.
Journal of Hand Surgery Global Online
2021;3(2):74–80. DOI: 10.1016/j.jhsg.2020.11.002.
Yamaguchi T, Takashima A, Nagashima K, Terashima M, Aizawa M, Ohashi M, Tanaka R, Yamada T,
Kinoshita T, Inada T, Ishiyama K, Ema A, Yuasa Y, Haruta S, Kakihara N, Nishikawa K, Yunome G, Satoh
T, Fukagawa T, Katai H, Boku N. Impact of preoperative chemotherapy as initial treatment for
advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology
(CY1) or localized peritoneal metastasis (P1a): A multi-institutional retrospective study.
Gastric Cancer
2021;24(3):701–709. DOI: 10.1007/s10120-020-01137-6.
Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh
H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E,
Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R,
Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K, on behalf of the PRIME-V study
group. Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle
in Japanese patients with type 2 diabetes mellitus: Sub-analysis of a prospective, randomized,
controlled study (PRIME-V study).
Journal of Diabetes Investigation
2021;12(2):200–206. DOI: 10.1111/jdi.13340.
Sato Y, Kobayashi T, Nishiumi S, Okada A, Fujita T, Sanuki T, Kobayashi M, Asahara M, Adachi M,
Sakai A, Shiomi H, Masuda A, Yoshida M, Takeuchi K, Kodama Y, Kutsumi H, Nagashima K, Honda K.
Prospective study using plasma apolipoprotein A2-isoforms to screen for high-risk status of
pancreatic cancer. Cancers
2020;12(9):2625. DOI: 10.3390/cancers12092625.
Nomura K, Minamizono S, Nagashima K, Ono M, Kitano N. Maternal body mass index and breastfeeding
non-initiation and cessation: a quantitative review of the literature.
Nutrients
2020;12(9):2684. DOI: 10.3390/nu12092684.
Imamura S, Inagaki T, Terada J, Nagashima K, Katsura H, Tatsumi K. Long-term efficacy of pulmonary
rehabilitation with home-based or low frequent maintenance programs in patients with chronic
obstructive pulmonary disease: a meta-analysis.
Annals of Palliative Medicine
2020;9(5):2606–2615. DOI: 10.21037/apm-19-581.
Ishibashi R, Takatsuna Y, Koshizaka M, Tatsumi T, Takahashi S, Nagashima K, Asaumi N, Arai M,
Shimada F, Tachibana K, Watanabe Y, Ishikawa K, Hoshino A, Yamamoto K, Kubota-Taniai M, Mayama T,
Yamamoto S, Yokote K. Safety and efficacy of ranibizumab and luseogliflozin combination therapy in
diabetic macular edema patients: protocol for a multicenter, randomized controlled, open-label
trial. Diabetes Therapy
2020;11(8):1891–1905. DOI: 10.1007/s13300-020-00854-6.
Ueshima K, Ogasawara S, Ikeda M, Yasui Y, Terashima T, Yamashita T, Obi S, Sato S, Aikata H, Ohmura
T, Kuroda H, Ohki T, Nagashima K, Ooka Y, Takita M, Kurosaki M, Chayama K, Kaneko S, Izumi N, Kato
N, Kudo M, Omata M. Hepatic arterial infusion chemotherapy versus sorafenib in patients with
advanced hepatocellular carcinoma.
Liver Cancer
2020;9(5):583–595. DOI: 10.1159/000508724.
Yamamoto S, Kato K, Daiko H, Kojima T, Hara H, Abe T, Tsubosa Y, Nagashima K, Aoki K, Mizoguchi Y,
Kitano S, Yachida S, Shiba S, Kitagawa Y. Feasibility study of nivolumab as neoadjuvant chemotherapy
for locally esophageal carcinoma: FRONTiER (JCOG1804E).
Future Oncology
2020;16(19):1351–1357. DOI: 10.2217/fon-2020-0189.
Nagata Y, Kato K, Miyamoto T, Hirano H, Shoji H, Iwasa S, Honma Y, Takashima A, Hamaguchi T,
Matsushita H, Nagashima K, Saruta M, Boku N. Safety and efficacy of cell-free and concentrated
ascites reinfusion therapy (CART) in gastrointestinal cancer patients with massive ascites treated
with systemic chemotherapy.
Supportive Care in Cancer
2020;28(12):5861–5869. 10.1007/s00520-020-05401-4.
Katsumata Y, Terada J, Matsumura T, Koshikawa K, Sakao S, Tomiyoshi G, Shinmen N, Nakamura R, Kuroda
H, Nagashima K, Kobayashi Y, Kobayashi E, Iwadate Y, Zhang X-M, Hiwasa T, Tatsumi K. Circulating
anti-sorting nexins 16 antibodies as an emerging biomarker of coronary artery disease in patients
with obstructive sleep apnea. Diagnostics
2020;10(2):71. DOI: 10.3390/diagnostics10020071.
Suichi T, Misawa S, Nagashima K, Sato Y, Iwai Y, Katayama K, Sekiguchi Y, Shibuya K, Amino H, Suzuki
Y-i, Tsuneyama A, Nakamura K, Kuwabara S. Lenalidomide treatment for thalidomide-refractory POEMS
syndrome: A prospective single-arm clinical trial.
Internal Medicine
2020;59(9):1149–1153. DOI: 10.2169/internalmedicine.3800-19.
Ishikawa M, Iwasa S, Aoki M, Imazeki H, Hirano H, Shoji H, Honma Y, Okita N, Nagashima K, Takashima
A, Kato K, Saruta M, Boku N. Retrospective comparison of nab-paclitaxel plus ramucirumab and
paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on
peritoneal metastasis.
Investigational New Drugs
2020;38(2):533–540. DOI: 10.1007/s10637-019-00822-3.
Iwase T, Sangai T, Fujimoto H, Sawabe Y, Matsushita K, Nagashima K, Sato Y, Nakagawa A, Masuda T,
Nagashima T, Ohtsuka M. Quality and quantity of visceral fat tissue are associated with insulin
resistance and survival outcomes after chemotherapy in patients with breast cancer.
Breast Cancer Research and Treatment
2020;179(2):435–443. DOI: 10.1007/s10549-019-05467-7.
Satomi NT, Honma Y, Nagashima K, Umezawa R, Ito Y, Hirano H, Shoji H, Takashima A, Iwasa S, Kato K,
Hamaguchi T, Itami J, Boku N. Risk factors of severe benign cicatricial stricture after definitive
chemoradiation for localized T3 esophageal carcinoma.
Anticancer Research
2020;40(2):1071–1077. DOI: 10.21873/anticanres.14045.
Honma Y, Nagashima K, Hirano H, Shoji H, Iwasa S, Takashima A, Okita N, Kato K, Boku N, Murakami N,
Inaba K, Ito Y, Itami J, Kanamori J, Oguma J, Daiko H. Clinical outcomes of locally advanced
esophageal neuroendocrine carcinoma treated with chemoradiotherapy.
Cancer Medicine
2020;9(2):595–604. DOI: 10.1002/cam4.2708.
Fujita M, Nagashima K, Takahashi S, Suzuki K, Fujisawa T, Hata A. Hand-held flow meter improves COPD
detectability regardless of using a conventional questionnaire: a split-sample validation study.
Respirology
2020;25(2):191–197. DOI: 10.1111/resp.13602.
Yamaguchi T, Takashima A, Nagashima K, Makuuchi R, Aizawa M, Ohashi M, Tashiro K, Yamada T,
Kinoshita T, Hata H, Kawachi Y, Kawabata R, Tsuji T, Hihara J, Sakamoto T, Fukagawa T, Katai H,
Higuchi K, Boku N. Efficacy of post-operative chemotherapy after resection leaving no
macroscopically visible disease of gastric cancer with peritoneal lavage cytology positive (CY1) or
localized peritoneum metastasis (P1a): a multicenter retrospective study.
Annals of Surgical Oncology
2020;27(1):284–292. DOI: 10.1245/s10434-019-07697-x.
Nomura K, Nagashima K, Suzuki T, Itoh H. Application of Japanese guidelines for gestational weight
gain to multiple pregnancy outcomes and its optimal range in 101,336 Japanese women.
Scientific Reports
2019;9(1):17310. DOI: 10.1038/s41598-019-53809-8.
Masuda K, Shoji H, Nagashima K, Yamamoto S, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa
S, Okita N, Takashima A, Kato K, Boku N. Correlation between immune-related adverse events and
prognosis in patients with gastric cancer treated with nivolumab.
BMC Cancer
2019;19(1):974. DOI: 10.1186/s12885-019-6150-y.
Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi
T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nagashima K,
Habuchi T. Changes in conditional net survival and dynamic prognostic factors in patients with newly
diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy.
Cancer Medicine
2019;8(15):6566–6577. DOI: 10.1002/cam4.2502.
Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi
T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nagashima K,
Habuchi T. Prognostic significance of early changes in serum biomarker levels in patients with newly
diagnosed metastatic prostate cancer.
Scientific Reports
2019;9(1):12071. DOI: 10.1038/s41598-019-48600-8.
Monma S, Kato K, Shouji H, Okita N, Takashima A, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Shimada Y,
Boku N, Nagashima K, Ito Y, Itami J. Gastric mucosal injury and hemorrhage after definitive
chemoradiotherapy for locally advanced esophageal cancer.
Esophagus
2019;16(4):402–407. DOI: 10.1007/s10388-019-00680-1.
Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh
H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E,
Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R,
Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K, On behalf of the PRIME-V study
group. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and
metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A
prospective, multicentre, open-label, blinded-endpoint, randomised controlled study (PRIME-V study).
Diabetes, Obesity and Metabolism
2019;21(8):1990–1995. DOI: 10.1111/dom.13750.
Fujita M, Nagashima K, Takahashi S, Hata A. Inequality within a community at the neighborhood level
and the incidence of mood disorders in Japan: a multilevel analysis.
Social Psychiatry and Psychiatric Epidemiology
2019;54(9):1125–1131. DOI: 10.1007/s00127-019-01687-w.
Aoki M, Shoji H, Nagashima K, Imazeki H, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima
A, Kato K, Higuchi K, Boku N. Hyperprogressive disease during nivolumab or irinotecan treatment in
patients with advanced gastric cancer.
ESMO Open
2019;4:e000488. DOI: 10.1136/esmoopen-2019-000488.
Matsumura T, Terada J, Yoshimura C, Koshikawa K, Kinoshita T, Yahaba M, Nagashima K, Sakao S,
Tatsumi K. Single-use suvorexant for treating insomnia during overnight polysomnography in patients
with suspected obstructive sleep apnea: a single-center experience.
Drug Design, Development and Therapy
2019;13:809–816. DOI: 10.2147/DDDT.S197237.
Hiramoto S, Tamaki T, Nagashima K, Hori T, Kikuchi A, Yoshioka A, Inoue A. Prognostic factors in
patients who received end-of-life chemotherapy for advanced cancer.
International Journal of Clinical Oncology
2019;24(4):454–459. DOI: 10.1007/s10147-018-1363-7.
Hashimoto J, Kato K, Ito Y, Kojima T, Akimoto T, Daiko H, Hamamoto Y, Matsushita H, Katano S, Hara
H, Tanaka Y, Saito Y, Nagashima K, Igaki H. Phase II feasibility study of preoperative concurrent
chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for
clinical stage II/III esophageal squamous cell carcinoma.
International Journal of Clinical Oncology
2019;24(1):60–67. DOI: 10.1007/s10147-018-1336-x.
Honma Y, Terauchi T, Tateishi U, Kano D, Nagashima K, Iwasa S, Takashima A, Kato K, Hamaguchi T,
Boku N, Shimada Y, Yamada Y. Imaging peritoneal metastasis of gastric cancer with
18F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept
study. British Journal of Radiology
2018;91(1089):20180259. DOI: 10.1259/bjr.20180259.
Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Medical costs attributable to overweight and
obesity in Japanese individuals.
Obesity Research & Clinical Practice
2018;12(5):479–484.
DOI: 10.1016/j.orcp.2018.06.002.
Nishi T, Kitahara H, Fujimoto Y, Nakayama T, Nagashima K, Hanaoka H, Kobayashi Y. Intravenous
nicorandil versus adenosine for fractional flow reserve measurement: A crossover, randomized study.
Heart and Vessels
2018;33(12):1570–1575. DOI: 10.1007/s00380-018-1197-2.
Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H,
Suichi T, Yokota T, Nishida Y, Kanouchi T, Kohara N, Kawamoto M, Ishii J, Kuwahara M, Suzuki H,
Hirata K, Kokubun N, Masuda R, Kaneko J, Yabe I, Sasaki H, Kaida K-i, Takazaki H, Suzuki N, Suzuki
S, Nodera H, Matsui N, Tsuji S, Koike H, Yamasaki R, Kusunoki S, for the Japanese Eculizumab Trial
for GBS (JET-GBS) Study Group. Safety and efficacy of eculizumab in Guillain–Barré
syndrome: a multicentre, double-blind, randomised phase 2 trial.
The Lancet Neurology
2018;17(6):519–529. DOI: 10.1016/S1474-4422(18)30114-5.
HOT
Fujita M, Sugiyama M, Sato Y, Nagashima K, Takahashi S, Mizogami M, Hata A. Hepatitis B virus
reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan.
Journal of Viral Hepatitis
2018;25(11):1312–1320. DOI: 10.1111/jvh.12933.
Matsumura T, Terada J, Kinoshita T, Sakurai Y, Yahaba M, Tsushima K, Sakao S, Nagashima K, Ozaki T,
Kobayashi Y, Hiwasa T, Tatsumi K. Circulating autoantibodies against neuroblastoma suppressor of
tumorigenicity 1 (NBL1): a potential biomarker for coronary artery disease in patients with
obstructive sleep apnea. PLoS ONE
2018;13(3):e0195015. DOI: 10.1371/journal.pone.0195015.
Yamaguchi T, Kato K, Nagashima K, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Ito Y, Itami J, Boku
N, Higuchi K. Type of second primary malignancy after achieving complete response by definitive
chemoradiation therapy in patients with esophageal squamous cell carcinoma.
International Journal of Clinical Oncology
2018;23(4):652–658. DOI: 10.1007/s10147-018-1258-7.
Watanabe K, Hirano S, Kojima K, Nagashima K, Mukai H, Sato T, Takemoto M, Matsumoto K, Iimori T,
Isose S, Omori S, Shibuya K, Sekiguchi Y, Beppu M, Amino H, Suichi T, Yokote K, Uno T, Kuwabara S,
Misawa S. Altered cerebral blood flow in the anterior cingulate cortex is associated with
neuropathic pain.
Journal of Neurology, Neurosurgery, and
Psychiatry
2018;89(10):1082–1087. DOI: 10.1136/jnnp-2017-316601.
Kotooka N, Kitakaze M, Nagashima K, Asaka M, Kinugasa Y, Nochioka K, Mizuno A, Nagatomo D, Mine D,
Yamada Y, Kuratomi A, Okada N, Fujimatsu D, Kuwahata S, Toyoda S, Hirotani S-i, Komori T, Eguchi K,
Kario K, Inomata T, Sugi K, Yamamoto K, Tsutsui H, Masuyama T, Shimokawa H, Momomura S-i, Seino Y,
Sato Y, Inoue T, Node K, On behalf of the HOMES-HF study investigators. The first multicenter,
randomized, controlled trial of home telemonitoring for Japanese patients with heart failure: home
telemonitoring study for patients with heart failure (HOMES-HF).
Heart and Vessels
2018;33(8):866–876. DOI: 10.1007/s00380-018-1133-5.
Inagaki T, Terada J, Yahaba M, Kawata N, Jujo T, Nagashima K, Sakao S, Tanabe N, Tatsumi K. Heart
rate and oxygen saturation change patterns during 6-min walk test in subjects with chronic
thromboembolic pulmonary hypertension.
Respiratory Care
2018;63(5):573–583. DOI: 10.4187/respcare.05788.
Sasaki Y, Iwasa S, Okazaki S, Goto M, Kojima Y, Naganuma A, Nagashima K, Nagai Y, Hirano H, Honma Y,
Takashima A, Kato K, Hamaguchi T. A phase II study of combination therapy with oral S-1 and
cisplatin in elderly patients with advanced gastric cancer.
Gastric Cancer
2018;21(3):439–445. DOI: 10.1007/s10120-017-0753-2.
Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T,
Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N. A double-blind
randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis
induced by highly emetogenic cisplatin-based chemotherapy.
International Journal of Clinical Oncology
2018;23(2):382–388. DOI: 10.1007/s10147-017-1200-4.
Kinoshita T, Yahaba M, Terada J, Matsumura T, Sakurai Y, Sakao S, Nagashima K, Tatsumi K. Impact of
arterial stiffness on WatchPAT variables in patients with obstructive sleep apnea.
Journal of Clinical Sleep Medicine
2018;14(3):319–325. DOI: 10.5664/jcsm.6970.
Korematsu S, Nagashima K, Sato Y, Nagao M, Hasegawa S, Nakamura H, Sugiura S, Miura K, Okada K,
Fujisawa T. "Spike" in acute asthma exacerbations during enterovirus D68 epidemic in Japan: A
nation-wide survey. Allergology International
2018;67(1):55–60. DOI: 10.1016/j.alit.2017.04.003.
Iizumi S, Takashima A, Narita Y, Tajika M, Muro K, Kawai S, Yasui H, Matsushima T, Takahari D,
Nagashima K, Boku N. Efficacy and safety of taxane-monotherapy in advanced gastric cancer refractory
to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.
Cancer Chemotherapy and Pharmacology
2017;80(3):575–582. DOI: 10.1007/s00280-017-3397-3.
Shiraishi H, Fujiwara Y, Kakuya T, Tsuta K, Motoi N, Miura N, Watabe Y, Watanabe S-i, Noro R,
Nagashima K, Huang W, Yamada T, Asamura H, Ohe Y, Honda K. Actinin-4 protein overexpression as a
predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma.
Biomarkers in Medicine
2017;11(9):721–731. DOI: 10.2217/bmm-2017-0150.
Honma Y, Hokamura N, Nagashima K, Sudo K, Shoji H, Iwasa S, Takashima A, Kato K, Hamaguchi T, Boku
N, Ito Y, Itami J, Koyanagi K, Igaki H, Tachimori Y. Clinical outcomes of resectable esophageal
cancer with supraclavicular lymph node metastases treated with curative intent.
Anticancer Research
2017;37(7):3741–3749. DOI: 10.21873/anticanres.11748.
Nishide A, Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Income-related inequalities in access
to dental care services in Japan.
International Journal of Environmental Research and
Public Health
2017;14(5):524. DOI: 10.3390/ijerph14050524.
Shoji H, Heike Y, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y,
Iwasa S, Takashima A, Kato K, Boku N, Honda K, Yamada T, Hamaguchi T. The peripheral immune status
of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer
patients receiving cisplatin-based chemotherapy.
Oncotarget
2017;8(56):95083–95094. DOI: 10.18632/oncotarget.18297.
Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Impact of geographic accessibility on
utilization of the annual health check-ups by income level in Japan: A multilevel analysis.
PLoS ONE
2017;12(5):e0177091. DOI: 10.1371/journal.pone.0177091.
Nomura K, Kido M, Tanabe A, Nagashima K, Takenoshita S, Ando K. Investigation of optimal weight gain
during pregnancy for Japanese Women.
Scientific Reports
2017;7(1):2569. DOI: 10.1038/s41598-017-02863-1.
Matsumura T, Terada J, Kinoshita T, Sakurai Y, Yahaba M, Ema R, Amata A, Sakao S, Nagashima K,
Tatsumi K, Hiwasa T. Circulating anti-coatomer protein complex subunit epsilon (COPE) autoantibodies
as a potential biomarker for cardiovascular and cerebrovascular events in patients with obstructive
sleep apnea.
Journal of Clinical Sleep Medicine
2017;13(3):393–400. DOI: 10.5664/jcsm.6488.
Koshizaka M, Ishikawa K, Ishikawa T, Kobayashi K, Takemoto M, Horikoshi T, Shimousa R, Takahashi S,
Nagashima K, Sato Y, Tatsuno I, Terano T, Hashimoto N, Kuribayashi N, Uchida D, Yokote K, on behalf
of the PRIME-V Study Investigators. Efficacy and safety of ipragliflozin and metformin for visceral
fat reduction in type 2 diabetes patients receiving treatment with dipeptidyl peptidase-4 inhibitors
in Japan: A study protocol for a prospective, multicenter, blinded-endpoint phase IV randomized
controlled trial (PRIME-V study). BMJ Open
2017;7(5):e015766. DOI: 10.1136/bmjopen-2016-015766.
Nishimura T, Iwasa S, Nagashima K, Okita N, Takashima A, Honma Y, Kato K, Hamaguchi T, Yamada Y,
Shimada Y, Boku N. Irinotecan monotherapy as third-line treatment for advanced gastric cancer
refractory to fluoropyrimidines, platinum, and taxanes.
Gastric Cancer
2017;20(4):655–662. DOI: 10.1007/s10120-016-0670-9.
Yamamoto Y, Yamaguchi S, Sasho T, Fukawa T, Akatsu Y, Akagi R, Yamaguchi T, Takahashi K, Nagashima
K, Takahashi K. Quantitative US elastography can be used to quantify mechanical and histologic
tendon healing in a rabbit model of achilles tendon transection.
Radiology
2017;283(2):408–417. DOI: 10.1148/radiol.2016160695.
Yamaguchi N, Misawa S, Sato Y, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T,
Yokota T, Nishida Y, Kohara N, Hirata K, Nishiyama K, Yabe I, Kaida K-I, Suzuki N, Nodera H, Tsuji
S, Koike H, Kira J-I, Hanaoka H, Kusunoki S, Kuwabara S, JET-GBS Group. A prospective, multi-center,
randomized phase II study to evaluate the efficacy and safety of eculizumab in patients with
Guillain-Barré syndrome (GBS): Japanese Eculizumab Trial for GBS (JET-GBS).
JMIR Research Protocols
2016;5(4):e210. DOI: 10.2196/resprot.6610.
Nishi T, Kitahara H, Fujimoto Y, Nakayama T, Sugimoto K, Nagashima K, Hanaoka H, Kobayashi Y.
Efficacy of intravenous nicorandil for fractional flow reserve assessment: Study protocol for a
crossover randomised trial. BMJ Open
2016;6(11):e012737. DOI: 10.1136/bmjopen-2016-012737.
Misawa S, Sato Y, Katayama K, Nagashima K, Aoyagi R, Sekiguchi Y, Sobue G, Koike H, Yabe I, Sasaki
H, Watanabe O, Takashima H, Nishizawa M, Kawachi I, Kusunoki S, Mitsui Y, Kikuchi S, Nakashima I,
Ikeda S-i, Kohara N, Kanda T, Kira J-i, Hanaoka H, Kuwabara S, for the Japanese POEMS Syndrome for
Thalidomide (J-POST) Trial Study Group. Safety and efficacy of thalidomide in patients with POEMS
syndrome: a multicentre, randomised, double-blind, placebo-controlled trial.
The Lancet Neurology
2016;15(11):1129–1137. DOI: 10.1016/S1474-4422(16)30157-0.
HOT
Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S,
Okita N, Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T. Pretreatment
immune status correlates with progression-free survival in chemotherapy-treated metastatic
colorectal cancer patients.
Cancer Immunology Research
2016;4(7):592–599. DOI: 10.1158/2326-6066.CIR-15-0298.
Sasaki Y, Akasu T, Saito N, Kojima H, Matsuda K, Nakamori S, Komori K, Amagai K, Yamaguchi T, Ohue
M, Nagashima K, Yamada Y. Prognostic and predictive value of extended
RAS mutation and mismatch repair status in stage III
colorectal
cancer. Cancer Science
2016;107(7):1006–1012. DOI: 10.1111/cas.12950.
Tanemura N, Uyama Y, Nagashima K, Suzuki T, Asahina Y, Kobayashi Y, Iyo M, Yokote K, Hanaoka H.
Comparison of drug use between clinical practice and regulatory approval: results in older Japanese
patients with rheumatoid arthritis, diabetes, high blood pressure, or depression.
Therapeutic Innovation & Regulatory Science
2016;50(6):743–750. DOI: 10.1177/2168479016648731.
Yamaguchi T, Iwasa S, Nagashima K, Ikezawa N, Hamaguchi T, Shoji H, Honma Y, Takashima A, Okita N,
Kato K, Yamada Y, Shimada Y. Comparison of panitumumab plus irinotecan and cetuximab plus irinotecan
for KRAS wild-type metastatic colorectal cancer.
Anticancer Research
2016;36(7):3531–3536. URL: http://ar.iiarjournals.org/content/36/7/3531.
Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Income related inequality of health care access
in Japan: A retrospective cohort study.
PLoS ONE
2016;11(3):e0151690. DOI: 10.1371/journal.pone.0151690.
Tawada A, Chiba T, Saito T, Ogasawara S, Suzuki E, Ooka Y, Arai M, Kanda T, Shinozaki M, Goto N,
Nagashima K, Yokosuka O. Utility of prediction scores for hepatocellular carcinoma in patients with
chronic hepatitis B treated with nucleos(t)ide analogues.
Oncology
2016;90(4):199–208. DOI: 10.1159/000444392.
Yamamoto Y, Yamaguchi S, Sasho T, Fukawa T, Akatsu Y, Nagashima K, Takahashi K. Quantitative
ultrasound elastography with an acoustic coupler for achilles tendon elasticity: measurement
repeatability and normative values.
Journal of Ultrasound in Medicine
2016;35(1):159–166. DOI: 10.7863/ultra.14.11042.
Naito S, Tanaka J, Nagashima K, Chang B, Hishiki H, Takahashi Y, Oikawa J, Nagasawa K, Shimojo N,
Ishiwada N. The impact of heptavalent pneumococcal conjugate vaccine on the incidence of childhood
community-acquired pneumonia and bacteriologically confirmed pneumococcal pneumonia in Japan.
Epidemiology and Infection
2016;144(3):494–506. DOI: 10.1017/S0950268815001272.
Aoyagi R, Hamada H, Sato Y, Suzuki H, Onouchi Y, Ebata R, Nagashima K, Terauchi M, Terai M, Hanaoka
H, Hata A, on behalf of the KAICA Trial investigators. Study protocol for a phase III multicentre,
randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of
immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial).
BMJ Open
2015;5(12):e009562. DOI: 10.1136/bmjopen-2015-009562.
Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Validity assessment of self-reported medication
use by comparing to pharmacy insurance claims.
BMJ Open
2015;5(11):e009490. DOI: 10.1136/bmjopen-2015-009490.
Iwasa S, Nagashima K, Yamaguchi T, Matsumoto H, Ichikawa Y, Goto A, Yasui H, Kato K, Okita N,
Shimada Y, Yamada Y. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and
leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled
analysis of four phase II studies.
Cancer Chemotherapy and Pharmacology
2015;76(3):605–614. DOI: 10.1007/s00280-015-2834-4.
Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Predictive power of a body shape index for
development of diabetes, hypertension, and dyslipidemia in Japanese adults: a retrospective cohort
study. PLoS ONE
2015;10(6):e0128972. DOI: 10.1371/journal.pone.0128972.
Utsumi H, Honma Y, Nagashima K, Iwasa S, Takashima A, Kato K, Hamaguchi T, Yamada Y, Shimada Y,
Kishi Y, Nara S, Esaki M, Shimada K. Bevacizumab and postoperative wound complications in patients
with liver metastases of colorectal cancer.
Anticancer Research
2015;35(4):2255–2261. URL: http://ar.iiarjournals.org/content/35/4/2255.
Takahashi N, Yamada Y, Furuta K, Nagashima K, Kubo A, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N,
Takashima A, Kato K, Hamaguchi T, Shimada Y. Association between serum ligands and the skin toxicity
of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer.
Cancer Science
2015;106(5):604–610. DOI: 10.1111/cas.12642.
Nagashima K, Yanai T, Iwasa S, Ohyanagi F, Kasai T, Minato K, Sakai H, Sakamoto C, Takeda K, Harada
D, Goto K, Yamamoto N. A double-blind randomized Phase II study of olanzapine 10 mg versus 5 mg for
emesis induced by highly emetogenic chemotherapy.
Japanese Journal of Clinical Oncology
2015;75(2):229–231. DOI: 10.1093/jjco/hyu191.
Shirakawa T, Kato K, Nagashima K, Nishikawa A, Sawada R, Takahashi N, Shoji H, Sasaki Y, Honma Y,
Iwasa S, Takashima A, Okita N, Hamaguchi T, Yamada Y, Shimada Y. A retrospective study of docetaxel
or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who
previously received fluoropyrimidine- and platinum-based chemotherapy.
Cancer Chemotherapy and Pharmacology
2014;74(6):1207–1215. DOI: 10.1007/s00280-014-2597-3.
Shoji H, Yamada Y, Taniguchi H, Nagashima K, Okita N, Takashima S, Honma Y, Iwasa S, Kato K,
Hamaguchi T, Shimada Y. Clinical impact of c-MET expression and genetic mutational status in
colorectal cancer patients after liver resection.
Cancer Science
2014;105(8):1002–1007. DOI: 10.1111/cas.12453.
Iwasa S, Nakajima TE, Nagashima K, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y. Lack of
association of proteinuria and clinical outcome in patients treated with bevacizumab for metastatic
colorectal cancer. Anticancer Research
2013;33(1):309–316. URL: http://ar.iiarjournals.org/content/33/1/309.
Horita Y, Yamada Y, Kato K, Hirashima Y, Akiyoshi K, Nagashima K, Nakajima TE, Hamaguchi T, Shimada
Y. Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic
colorectal cancer: AVASIRI trial.
International Journal of Clinical Oncology
2012;17(6):604–609. DOI: 10.1007/s10147-011-0331-2.
Okita NT, Esaki T, Baba E, Sakai D, Tokunaga S, Takiuchi H, Mizunuma N, Nagashima K, Kato K. A
multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line
treatment of patients with metastatic colorectal cancer.
Investigational New Drugs
2012;30(5):2026–2031. DOI: 10.1007/s10637-011-9779-1.
Fujie H, Niu K, Ohba M, Tomioka Y, Kitazawa H, Nagashima K, Ohrui T, Numasaki M. A distinct
regulatory role of Th17 cytokines IL-17A and IL-17F in chemokine secretion from lung microvascular
endothelial cells. Inflammation
2012;35(3):1119–1131. DOI: 10.1007/s10753-011-9419-0.
Nakajima TE, Yoshida H, Okamoto N, Nagashima K, Taniguchi H, Yamada Y, Shimoda T, Masutomi K.
Nucleostemin and TWIST as predictive markers for recurrence after neoadjuvant chemotherapy for
esophageal carcinoma. Cancer Science
2012;103(2):233–238. DOI: 10.1111/j.1349-7006.2011.02142.x.
Tanai C, Nakajima TE, Nagashima K, Kato K, Hamaguchi T, Yamada Y, Muro K, Shirao K, Kunitoh H,
Matsumura Y, Yamamoto S, Shimada Y. Characteristics and outcomes of patients with advanced gastric
cancer who declined to participate in a randomized clinical chemotherapy trial.
Journal of Oncology Practice
2011;7(3):148–153. DOI: 10.1200/JOP.2010.000106.
Hashimoto K, Takashima A, Nagashima K, Okazaki S, Nakajima TE, Kato K, Hamaguchi T, Yamada Y,
Shimada Y. Progression-free survival in first-line chemotherapy is a prognostic factor in
second-line chemotherapy in patients with advanced gastric cancer.
Journal of Cancer Research and Clinical Oncology
2010;136(7):1059–1064. DOI: 10.1007/s00432-009-0752-8.
Preprint(s)
Nagashima K, Noma H, Furukawa TA. pimeta: an R package of prediction intervals for random-effects
meta-analysis. [arXiv:2110.07856]
Yuda S, Kato K, Sasaki Y, Takahashi N, Shoji H, Takashima A, Okita N, Honma Y, Iwasa S, Hamaguchi T,
Nagashima K, Boku N. Risk factors for FN, mucositis and esophagitis of combination chemotherapy with
docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer. DOI: 10.21203/rs.3.rs-62898/v1.
[R] RevGadgets Package
as a contributor (postprocessing gadgets for output generated by RevBayes; CRAN Task View: Phylogenetics)
[R] pimeta Package
(prediction intervals for random-effects meta-analysis; Nagashima K, et al. Stat Methods Med Res
2019; CRAN Task View: MetaAnalysis)
Kimura R, Nomura S, Nagashima K, Sato Y. A comparison of asymptotic and re-randomization tests under
non-proportional hazards scenarios with minimization method. The 44th Annual Conference of the
International Society for Clinical Biostatistics (ISCB 44), Aug. 30, 2023, Milan, Italy.
Nagashima K. pimeta: Prediction Intervals for Random-Effects Meta-Analysis. Evidence Synthesis and
Meta-Analysis in R Conference (ESMARConf 2023), Mar. 27–31, 2023, Virtual. (Invited Lecture)
Noma H, Nagashima K. Improved Monte Carlo inference methods for network meta-analysis. The 12th
International Conference of the ERCIM WG on Computational and Methodological Statistics
(CMStatistics 2019), Dec. 15, 2019, London, UK. (Poster) [Abstract]
Hamaguchi Y, Noma H, Nagashima K. Frequentist performances of the Bayesian prediction intervals for
random effects meta-analysis. 40th Annual Conference of the International Society for Clinical
Biostatistics (ISCB 40), Jul. 14–18, 2019, Leuven, Belgium. (Poster)
Noma H, Nagashima K. Asymptotic behaviors of the Mantel–Haenszel estimators and their robust
variance estimators when the common effect assumptions are violated. ENAR 2016 Spring Meeting, Mar.
6–9, 2016; JW Marriott Austin, Texas. (Poster) [Abstract]
Noma H, Nagashima K. Asymptotic behaviors of the Mantel–Haenszel estimators under the common
effect assumptions violated. Kyoto International Conference on Modern Statistics in the 21st
Century, Nov. 17–18, 2014; Kyoto International Conference Center, Kyoto.
Nagashima K, Sato Y. Information criterion for Firth-type penalized partial likelihood in Cox
regression. The 27th International Biometric Conference, Jul. 6–11, 2014; Firenze Fiera,
Italy. (Poster) [Abstract]
Nagashima K, Sato Y, Hamada C. A high-speed method for population pharmacokinetic data analysis in
genome-wide pharmacogenomic studies. The 26th International Biometric Conference, Aug. 26–31,
2012; Kobe Internatioanl Conference Center Kobe, Japan. (Poster) [Abstract]
Nagashima K, Sato Y, Hamada C. Studentized modified maximum contrast method for unequal sample sizes
in pharmacogenomics studies. The 25th International Biometric Conference, Dec. 5-10, 2010; Federal
University of Santa Catarina, Florianópolis, SC, Brazil. [Abstract]
Sato Y, Laird NM, Kato R, Nagashima K, Hamada C, Yoshimura I, Sakamoto H, Yoshida T. Modified
maximum contrast method to detect pharmacokinetics-related genes in pharmacogenomics studies. The 28th
Annual Conference of the International Society for Clinical Biostatistics (ISCB 28), Aug. 2, 2007,
Alexandroupolis, Greece.
Medical Researches
Tsushima T, Yamamoto S, Kato K, Daiko H, Hara H, Kojima T, Abe T, Tsubosa Y, Kawakubo H, Yoshii T,
Fujita T, Kadowaki S, Matsuda S, Nagashima K, Aoki K, Yachida S, Kitagawa Y. Efficacy of neoadjuvant
CF or DCF, FLOT plus nivolumab for resectable locally advanced esophageal squamous cell carcinoma
(JCOG1804E: FRONTiER). The 20th ISDE World Congress for Esophageal Diseases, Sep 22–24, 2024;
Edinburgh International Convention Centre (EICC), in Edinburgh, Scotland. (Poster) [Abstract]
Takahashi N, Hara H, Nagashima K, Hirata K, Masuishi T, Matsumoto T, Kawakami H, Yamazaki K, Hironaka
S, Boku N, Muro M. Randomized phase II trial of trifluridine/tipiracil plus ramucirumab versus
trifluridine/tipiracil for pre-treated patients with advanced gastric or gastroesophageal junction
adenocarcinoma (RETRIEVE study, WJOG15822G). ESMO Gastrointestinal Cancers Congress 2024, Jun.
26–29 2024; ICM-International Congress Center of the Munich Messe, Munich, Germany. (Poster) [Abstract]
Okui J, Nagashima K, Matsuda S, Sato Y, Kawakubo H, Takeuchi M, Hirata K, Yamamoto S, Nomura M,
Tsushima T, Takeuchi H, Kato K, Kitagawa Y. Investigation of synergistic effects in trials of
combination therapies with immune-checkpoint inhibitors in advanced esophageal squamous cell
carcinoma. ESMO Gastrointestinal Cancers Congress 2024, Jun. 26–29 2024;
ICM-International Congress Center of the Munich Messe, Munich, Germany. (Poster) [Abstract]
Muto M, Nomura M, Sakanaka K, Shimizu J, Ohashi S, Watanabe A, Katada C, Amanuma Y, Minashi K, Kato K,
Kojima T, Nagashima K, Kim I, Tada H, Nakakura A, Sasaki H. Effect of nivolumab combined with
definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic
subtype could be its biomarker—The NOBEL trial. 2024 ASCO Annual Meeting, May 29– Jun. 3, 2023;
McCormick Place, Chicago, Illinois. (Poster) [Abstract]
Kudo-Saito C, Boku N, Shoji H, Imazeki H, Nagashima K, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y,
Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Aoki K, Muro K. IL33-ST2 axis as a diagnostic
and therapeutic biomarker in nivolumab therapy for advanced gastric cancer. 2024 ASCO Annual Meeting,
May 29– Jun. 3, 2023; McCormick Place, Chicago, Illinois. (Poster) [Abstract]
Hirano H, Yamada Y, Nagashima K, Hiraoka N, Sekine S, Takahashi N, Azuma M, Iwasa S, Kanato K, Machida
N, Kinoshita T, Hata H, Kawakami H, Takahari D, Ojima T, Kadowaki S, Boku N, Kurokawa Y, Terashima M,
Yoshikawa T. Impact of PD-L1 expression on survival in patients with unresectable/recurrent gastric
cancer receiving first-line chemotherapy without immune checkpoint inhibitors. ASCO 2024
Gastrointestinal Cancers Symposium, Jan. 18–20, 2024; Moscone West Building, San Francisco, CA.
(Poster) [Abstract]
Okui J, Nagashima K, Matsuda S, Sato Y, Okamura A, Kawakubo H, Muto M, Kakeji Y, Kono K, Takeuchi H,
Watanabe M, Doki Y, Bamba T, Fukuda T, Fujiwara H, Sato S, Noma K, Miyata H, Fujita T, Kitagawa Y.
Recurrence-free survival as a surrogate for overall survival in esophageal squamous cell carcinoma:
Nationwide real-world data from Japan. ASCO 2024 Gastrointestinal Cancers Symposium, Jan. 18–20,
2024; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Shimozaki K, Nakayama I, Takahari D, Nagashima K, Yoshino K, Fukuda K, Fukuoka S, Osumi H, Ogura M,
Wakatsuki T, Ooki A, Shinozaki E, Chin K, Yamaguchi K. Efficacy and safety of trastuzumab deruxtecan
and nivolumab as third- or later-line treatment for HER2-positive advanced gastric cancer: A
single-institution retrospective study. ASCO 2024 Gastrointestinal Cancers Symposium, Jan.
18–20, 2024; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Yoshii T, Yamamoto S, Kato K, Daiko H, Hara H, Kojima T, Abe T, Tsubosa Y, Kawakubo H, Fujita T,
Kadowaki S, Tsushima T, Matsuda S, Nagashima K, Aoki K, Yachida S, Kitagawa Y. FRONTiER: A feasibility
trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma
(JCOG1804E)—Primary safety and short-term efficacy results for cohort E. ASCO 2024 Gastrointestinal
Cancers Symposium, Jan. 18–20, 2024; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Kudo-Saito C, Boku N, Shoji H, Imazeki H, Nagashima K, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y,
Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Aoki K, Muro K. The FSTL1-DIP2A axis as a
promising target in the anti-PD1 therapy of advanced gastric cancer. SITC 38th Annual Meeting (SITC
2023), Nov. 1–5, 2023; San Diego Convention Center, San Diego, CA. [Abstract]
Takahari D, Shoji H, Ooki A, Hirano H, Okita NT, Nagashima K, Adachi J, Yamaguchi K, Kato K, Boku N. A
phase I study of pevonedistat plus capeOX in patients with advanced gastric cancer refractory to
platinum (NCCH-1811). ESMO Congress 2023, Oct. 20–24, 2023; IFEMA Madrid, Madrid, Spain.
(Poster) [Abstract]
Yamamoto K, Hirose T, Takashima A, Yamazaki K, Yukami H, Uetake H, Tsuda M, Suto T, Moriwaki T,
Sugimoto N, Ojima H, Takii Y, Yasui H, Esaki T, Tsuji A, Goto M, Sawada R, Otsu S, Shinozaki K,
Nagashima K, Shimada Y. First-line treatment with CET/PAN vs. BEV in elderly patients with RAS WT
mCRC: A multicenter real-world observational study by the Japanese Society for Cancer of the Colon and
Rectum. ESMO Congress 2023, Oct. 20–24, 2023; IFEMA Madrid, Madrid, Spain.
(Poster) [Abstract]
Hirose T, Takashima A, Yamazaki K, Yukami H, Uetake H, Tsuda M, Suto T, Moriwaki T, Sugimoto N, Ojima
H, Takii Y, Yasui H, Esaki T, Tsuji A, Goto M, Sawada R, Otsu S, Shinozaki K, Nagashima K, Shimada Y.
Tumor response as a predictor of survival for RAS-WT left-sided mCRC administered first-line
molecularly targeted drugs: An observational study by the Japanese Society for Cancer of the Colon and
Rectum. ESMO Congress 2023, Oct. 20–24, 2023; IFEMA Madrid, Madrid, Spain.
(Poster) [Abstract]
Kashiro A, Kobayashi M, Oh T, Nagashima K, Takeuchi K, Nara S, Hijioka S, Morizane C, Kikuchi S, Kato
S, Kato K, Ochiai H, Obata D, Konishi H, Matsuyama K, Kutsumi H, Honda K. Clinical development of a
blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer. European
Pancreatic Club 2023, Jun. 28–Jul. 1 2023; Congress Centrum Alpbach, Alpbach, Austria. (Poster)
[Abstract]
Yamamoto K, Hirose T, Takashima A, Yamazaki K, Yukami H, Uetake H, Tsuda M, Suto T, Moriwaki T,
Sugimoto N, Ojima H, Takii Y, Yasui H, Esaki T, Tsuji A, Goto M, Sawada R, Otsu S, Shinozaki K,
Nagashima K, Shimada Y. First-line treatment with CET/PAN vs. BEV in elderly patients with RAS WT
mCRC: A multicenter real-world observational study by the Japanese Society for Cancer of the Colon and
Rectum. ESMO World Congress on Gastrointestinal Cancers 2023, Jun. 28–Jul. 1 2023;
Centre de Convencions Internacional de Barcelona, Barcelona, Spain. (Poster) [Abstract]
Muto M, Minashi K, Yano T, Amanuma Y, Ishihara R, Watanabe A, Katada C, Yamatsuji T, Matsushima K,
Doyama H, Ando T, Nishimura Y, Sakanaka K, Tsunoda S, Ohashi S, Shimizu J, Tada H, Uozumi R, Nagashima
K, Sasaki H. Expression molecular subtype as a predictor of outcomes of chemoradiotherapy for
esophageal cancer. 2023 ASCO Annual Meeting, Jun. 2–6, 2023; McCormick Place, Chicago, Illinois.
(Poster) [Abstract]
Yamada Y, Kamada A, Kabeya Y, Yoshida S, Harada H, Urakawa N, Kanaji S, Nakamura Y, Nagashima K,
Takeuchi H, Doki Y, Kitagawa Y, Kodera Y, Kakeji Y. Development of an artificial intelligence
algorithm for adjuvant chemotherapy based on a nationwide registry of patients with gastric cancer by
the Japanese Gastric Cancer Association (JGCA). 2023 ASCO Annual Meeting, Jun. 2–6, 2023;
McCormick Place, Chicago, Illinois. (Poster) [Abstract]
Tsugaru K, Boku N, Kudo-Saito C, Shoji H, Imazeki H, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T,
Okano N, Narita Y, Yamamoto Y, Kizawa R, Nagashima K, Aoki K, Muro K. LAG3-related factors to predict
response to nivolumab monotherapy in advanced gastric cancer (WJOG10417GTR study). ASCO 2023
Gastrointestinal Cancers Symposium, Jan. 19–21, 2023; Moscone West Building, San Francisco, CA.
(Poster) [Abstract]
Yano T, Amanuma Y, Minashi K, Komatsu M, Nagashima K, Shimizu J, Ishihara R, Watanabe A, Yamatsuji
T, Matsushima K, Doyama H, Ando T, Nishimura Y, Sasaki H, Muto M. Association between endogenous
subtype classification for esophageal squamous cell carcinoma and outcome of chemoradiotherapy. The
18th ISDE World Congress for Esophageal Diseases, Sep 26–28, 2022; Virtual. (Poster) [Abstract]
Oka H, Nagashima K, Nishi H, Kumai Y, Iijima H, Okami K, Shimizu Y, Kano S, Ito K, Yamazaki T,
Takahashi H, Oridate N, Yokota T, Koyama T, Kiyota N, Kato K, Kadowaki S, Honma Y. Clinical outcomes
in patients with recurrent or metastatic head and neck squamous cell carcinoma after
failure of platinum and nivolumab: A multicenter retrospective study. ESMO Congress 2022,
Sep. 9–13, 2022, Paris, France. (Poster) [Abstract]
Boku N, Kudo-Saito C, Imazeki H, Shoji H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T,
Okano N, Narita Y, Yamamoto Y, Kizawa R, Nagashima K, Aoki K, Muro K. Prognostic impact of myeloid
subsets in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study). ESMO Congress 2022,
Sep. 9–13, 2022, Paris, France. (Poster) [Abstract]
Shoji H, Boku N, Kudo-Saito C, Nagashima K, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki
T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Imazeki H, Aoki K, Muro K. Profiling of myeloid cells
associated with prognosis in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study).
ESMO Congress 2022, Sep. 9–13, 2022, Paris, France. (Poster) [Abstract]
Kobayashi T, Sato Y, Nishiumi S, Kodama Y, Nagashima K, Honda K. Prospective study of plasma
apolipoprotein A2-ATQ/AT to screen for high-risk individuals of pancreatic cancer. European Pancreatic
Club 2022, Jun. 22–25 2022, Kiev, Ukraine (virtual). [Abstract]
Yamada Y, Kobayashi H, Nagashima K, Sugihara K. Effect of adjuvant chemotherapy in patients with
stage III colon cancer based on the Multi-Institutional Registry of Large Bowel Cancer in Japan.
2022 ASCO Annual Meeting, Jun. 3–7, 2022; McCormick Place, Chicago, Illinois. (Poster) [Abstract]
Kadowaki S, Aoki M, Suzuki T, Takahashi N, Shirasu H, Ando T, Yamamoto Y, Kawakami K, Kito Y,
Matsumoto T, Shimozaki K, Miyazaki Y, Yamaguchi T, Akiyoshi K, Baba E, Makiyama A, Nakashima K,
Sugimoto N, Nagashima K, Boku N. Association of disease progression pattern during third-line
chemotherapy with nivolumab with poor prognosis in advanced gastric cancer: A multicenter
retrospective study in Japan. ASCO 2022 Gastrointestinal Cancers Symposium, Jan. 20–22, 2022;
Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Matsuda S, Yamamoto S, Kato K, Daiko H, Kojima T, Hara H, Abe T, Tsubosa Y, Kawakubo H, Nagashima K,
Aoki K, Yachida S, Kitagawa Y. FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or
DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)—Short-term results for
cohorts C and D. ASCO 2022 Gastrointestinal Cancers Symposium, Jan. 20–22, 2022; Moscone West
Building, San Francisco, CA. (Poster) [Abstract]
Shimozaki K, Hirata K, Sato T, Nakamura M, Kato K, Hirano H, Kumekawa Y, Hino K, Kawakami K, Kito Y,
Matsumoto T, Kawakami T, Komoda M, Nagashima K, Sato Y, Yamazaki K, Hironaka S, Hamamoto Y, Takaishi
H, Muro K. WJOG13219G: Triplet versus doublet in patients with previously untreated
BRAFV600E-mutant metastatic colorectal cancer: A multi-institutional real-world
data analysis (BRACELET study). ASCO 2022 Gastrointestinal Cancers Symposium, Jan. 20–22,
2022; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi
T, Ishidoya S, Shimoda J, Sato H, Mituzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nagashima K,
Habuchi T. Changes in the conditional net survival and dynamic prognostic factors in patients with
newly diagnosed metastatic prostate cancer. The 2021 AUA Annual Meeting 2021, Sep. 10–13,
2021; Virtual. (Poster) [Abstract]
Kumagai K, Yagi S, Yamaguchi T, Nagashima K, Nomura T, Watanabe M, Makuuchi R, Kawakami K, Otsuka S,
Matsushima T, Kadowaki S, Haruta S, Cho H, Yamada T, Kakihara N, Imai Y, Fukunaga H, Saeki Y, Kanaji
S, Boku N, Goto M. The efficacy of chemotherapy for gastric cancer with early recurrence during or
after adjuvant S-1. ESMO Congress 2022, Jun. 30–Jul. 3, 2021, Virtual. (Poster) [Abstract]
Ito T, Takashima A, Shirasu H, Yukami H, Uetake H, Tsuda M, Sudo T, Moriwaki T, Sugimoto N, Ojima H,
Takii Y, Yasui H, Ezaki T, Tsuji A, Goto M, Saruta M, Ootsu S, Shinozaki K, Nagashima K, Shimada Y.
Predictive role of tumor location in 1st-line treatment of colorectal cancer: a multicenter
retrospective study of JSCCR. 2021 the Japanese Society of Medical Oncology Annual Meeting, Feb. 20,
2021; Virtual.
Yamamoto S, Kato K, Daiko H, Kojima T, Hara H, Abe T, Tsubosa Y, Kawakubo H, Fujita T, Fukuda T,
Kadowaki S, Tsushima T, Hamamoto Y, Nagashima K, Aoki K, Mizoguchi Y, Kitano S, Yachida S, Shiba S,
Kitagawa Y. FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for
locally advanced esophageal carcinoma (JCOG1804E)—The short-term results of cohort A and B.
ASCO 2021 Gastrointestinal Cancers Symposium, Jan. 15–17, 2021; Virtual. (Poster) [Abstract]
Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi
T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nagashima K,
Habuchi T, Michinoku Japan Urological Cancer Study Group. Changes in conditional net survival and
dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer. ASCO 2020
Genitourinary Cancers Symposium, Feb. 13–15, 2020; Moscone West Building, San Francisco, CA.
(Poster) [Abstract]
Suzuki T, Aoki M, Shirasu H, Takahashi N, Nakatsuka R, Ando T, Kito Y, Yamamoto Y, Kawakami K,
Matsumoto T, Shimozaki K, Nagase M, Yamaguchi T, Negoro Y, Tamura T, Amanuma Y, Esaki T, Miura Y,
Nagashima K, Boku N. Hyperprogressive disease during nivolumab chemotherapy in metastatic gastric
cancer: multicenter retrospective study in Japan. ASCO 2020 Gastrointestinal Cancers Symposium, Jan.
23–25, 2020; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Nakayama I, Shoji H, Hara H, Esaki T, Machida N, Nagashima K, Aoki K, Honda K, Takahari D, Miyamoto
T, Boku N, Kato K. Correlation of tumor mutation with efficacy in patients with gastric cancer who
received nivolumab and ramucirumab combination therapy. ASCO 2020 Gastrointestinal Cancers
Symposium, Jan. 23–25, 2020; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Honda K, Kobayashi T, Sato Y, Nishiumi S, Okaya S, Takeuchi K, Nagashima K, Yoshida M.
Stratification of pancreatic cancer risk in the general population using an apolipoprotein A2
isoform blood test. 50th Anniversary Meeting American Pancreatic Association & Japan Pancreas
Society, Nov. 7, 2019, Maui, Hawaii. (Poster) [Abstract]
Yamamoto S, Kato K, Daiko H, Kojima T, Hara H, Abe T, Tsubosa Y, Nagashima K, Kitagawa K. FRONTiER:
A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal
carcinoma. ESMO Congress 2019, Sep. 29, 2019, Barcelona, Spain. (Poster) [Abstract]
Hiramoto S, Kikuchi A, Hori T, Yoshioka A, Nagashima K. Associations between primary cancer site,
metastatic site, comorbidity, and details of symptoms and treatment in advanced gastrointestinal
cancer patients at end-of-life. ESMO World Congress on Gastrointestinal Cancer 2019, Jul. 3–6,
2019; Centre de Convencions Internacional de Barcelona, Barcelona, Spain. (Poster) [Abstract]
Hiramoto S, Nagashima K, Hori T, Kikuchi A, Yoshioka A. Association between prognosis and
discontinuation by image diagnosis for advanced gastrointestinal cancer patients who received
end-of-life chemotherapy. ESMO World Congress on Gastrointestinal Cancer 2019, Jul. 3–6, 2019;
Centre de Convencions Internacional de Barcelona, Barcelona, Spain. (Poster) [Abstract]
Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H,
Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N. Correlation between immune-related adverse
events and prognosis in patients with gastric cancer treated with nivolumab. 2019 ASCO Annual
Meeting, May 31–Jun. 4, 2019; McCormick Place, Chicago, Illinois. (Poster) [Abstract]
Hara H, Shoji H, Takahari D, Esaki T, Machida N, Nagashima K, Aoki K, Honda K, Miyamoto T, Boku N,
Kato K. Phase I/II study of ramucirumab plus nivolumab in patients in second line treatment for
advanced gastric adenocarcinoma (NivoRam study). ASCO 2019 Gastrointestinal Cancers Symposium, Jan.
17–19, 2019; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Kumagai K, Yamaguchi T, Takashima A, Nagashima K, Kano Y, Terashima M, Yabusaki H, Nishikawa K,
Tanabe K, Yunome G, Kawachi Y, Yamada T, Fukunaga H, Kinoshita T, Watanabe M, Taniguchi H, Sakamoto
T, Ishiyama K, Boku N. Comparison between S-1 monotherapy and S-1 plus cisplatin as post-operative
chemotherapy after R0 resection for stage IV gastric cancer patients with oligo-metastasis: a
multicenter retrospective study. ASCO 2019 Gastrointestinal Cancers Symposium, Jan. 17–19,
2019; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Ogasawara S, Ueshima K, Ikeda M, Yasui Y, Terashima T, Yamashita T, Obi S, Sato S, Aikata H, Ohmura
T, Kuroda H, Ohki T, Nagashima K, Kurosaki M, Chayama K, Kaneko S, Izumi N, Kato N, Kudo M, Omata M.
Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular
carcinoma: a Japanese multi-center large cohort study. ASCO 2019 Gastrointestinal Cancers Symposium,
Jan. 17–19, 2019; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Kita S, Takashima A, Hirano H, Aoki M, Imazeki H, Ishikawa M, Shoji H, Honma Y, Iwasa S, Okita N,
Kato K, Nagashima K, Boku N. CT image features of peritoneal metastasis and outcomes of the advanced
gastric cancer patients receiving second-line chemotherapy. ESMO Asia 2018 Congress, Nov. 24, 2018;
Suntec Singapore Convention & Exhibition Centre, Singapore. [Abstract]
Sato Y, Kobayashi T, Nishiumi S, Okaya S, Yoshida M, Kodama Y, Nagashima K, Honda K. Usefulness of
the first screening using apolipoprotein A2 isoforms as the enrichment strategy for pancreatic
cancer and its risk diseases. ESMO 2018 Congress, Oct. 19–23, 2018; Messe Munich, Munich,
Germany. [Abstract]
Misawa S, Sato Y, Katayama K, Nagashima K, Sekiguchi Y, Amino H, Suichi T, Kuwabara S. The safety
and efficacy of thalidomide treatment prior to autologous stem-cell transplantation in POEMS
syndrome. 2018 Peripheral Nerve Society Annual Meeting, Jul. 21–25, 2018; Baltimore, Maryland.
(Poster) [Abstract]
Esaki T, Shoji H, Takahari D, Hara H, Machida N, Nagashima K, Aoki K, Honda K, Miyamoto T, Boku N,
Kato K. Preliminary result of p1/2 study of ramucirumab plus nivolumab in patients with pretreated
advanced gastric carcinoma. 2018 the Japanese Society of Medical Oncology Annual Meeting, Jul.
19–21, 2018; Kobe Convention Center, Kobe. [Abstract]
Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yokoh H,
Kobayashi A, Onishi S, Kobayashi K, Ogino J, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M,
Ide K, Ide S, Baba Y, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Takemoto M, Yokote K.
Comparing the effects of ipragliflozin and metformin on visceral fat reduction in patients with type
2 diabetes inadequately controlled with sitagliptin–a prospective, multicenter, blinded-endpoint,
randomized controlled study in Japan (PRIME-V study). American Diabetes Association, the 78th
Scientific Sessions, Jun 22–26, 2018; Orange County Convention Center, Orlando, FL. [Abstract]
Takahari D, Shoji H, Hara H, Esaki T, Machida N, Nagashima K, Aoki K, Honda K, Miyamoto T, Boku N,
Kato K. Preliminary result of phase 1/2 study of ramucirumab plus nivolumab in patients with
previously treated advanced gastric adenocarcinoma (NivoRam study). 2018 ASCO Annual Meeting, Jun
1–5, 2018; McCormick Place, Chicago, Illinois. (Poster) [Abstract]
Aizawa M, Yamaguchi T, Takashima A, Nagashima K, Ema A, Yuasa Y, Haruta S, Taniguchi H, Kobayashi D,
Nishikawa K, Yunome G, Takagi M, Niwa H, Yamada T, Hato S, Fukagawa T, Boku N, Katai H. Comparison
of S-1 and S-1 plus cisplatin as post-operative chemotherapy for gastric carcinoma with peritoneal
lavage cytology positive or localized peritoneum metastasis: A multicenter retrospective study. ASCO
2018 Gastrointestinal Cancers Symposium, Jan. 18–20, 2018; Moscone West Building, San
Francisco, CA. (Poster) [Abstract]
Makuuchi R, Yamaguchi T, Takashima A, Nagashima K, Yamada T, Kinoshita T, Hata H, Kawachi Y,
Kawabata R, Tsuji T, Hirabayashi N, Sakamoto T, Inada T, Ishiyama K, Fukagawa T, Boku N, Katai H.
The impact of pre-operative chemotherapy in patients with peritoneal lavage cytology positive or
localized peritoneum metastasis for gastric cancer: A multicenter retrospective study. ASCO 2018
Gastrointestinal Cancers Symposium, Jan. 18–20, 2018; Moscone West Building, San Francisco,
CA. (Poster) [Abstract]
Iwase T, Sangai T, Nagashima T, Sakakibara M, Fujimoto H, Sawabe Y, Nagashima K, Otsuka M. The
quality and quantity of visceral fat tissue are associated with insulin resistance and survival
outcome after chemotherapy for patients with early-stage breast cancer. 2017 San Antonio Breast
Cancer Symposium, Dec 5–9, 2017; Gonzales Convention Center, San Antonio, TX. (Poster) [Abstract]
Misawa S, Katayama K, Sato Y, Nagashima K, Sekiguchi Y, Suichi T, Amino H, Hanaoka H, Kuwabara S.
Pre-transplant induction thalidomide treatment in poems syndrome: An open-labell phase II clinical
trial. The XXIII World Congress of Neurology (WCN 2017), Sep 16–21, 2017; International
Conference Center Kyoto, Kyoto. [Abstract]
Suichi T, Misawa S, Nagashima K, Sekiguchi Y, Shibuya K, Watanabe K, Kuwabara S. Safety and efficacy
of lenalidomide for intractable/recurrent poems syndrome: An open label pilot study. The XXIII World
Congress of Neurology (WCN 2017), Sep 16–21, 2017; International Conference Center Kyoto,
Kyoto. [Abstract]
Shoji H, Miyamoto H, Hara H, Takahari D, Machida N, Esaki T, Nagashima K, Aoki K, Honda K, Nagata Y,
Miyamoto T, Boku N, Kato K. A phase 1/2 study of ramucirumab plus nivolumab in patients with
previously treated advanced gastric adenocarcinoma. ESMO 2017 Congress, Sep. 8–12, 2017; IFEMA
- Feria de Madrid, Spain. (Poster)
Sasaki Y, Kato K, Hirano H, Shoji H, Honma Y, Iwasa S, Takashima A, Hamaguchi T, Nagashima K, Boku
N. Evaluation of α-1-acid glycoprotein as a prognostic marker and as a predictive biomarker
for severe neutropenia induced by docetaxel in esophageal carcinoma patients. AACR Annual Meeting
2017; Apr. 1–5, 2017; Walter E. Washington Convention Center, Washington, D. C. (Poster) [Abstract]
Terazawa T, Iwasa S, Sasaki Y, Okazaki S, Goto M, Kojima Y, Naganuma A, Nagashima K, Hirano H, Honma
Y, Takashima A, Kato K, Hamaguchi T. A multicenter phase II study of combination therapy with oral
S-1 plus cisplatin in elderly patients with advanced gastric cancer. ASCO 2017 Gastrointestinal
Cancers Symposium, Jan. 19–21, 2017; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Tsushita N, Honma Y, Nagashima K, Miyamoto T, Nakamura S, Umezawa R, Ito Y, Shoji H, Takashima A,
Iwasa S, Kato K, Hamaguchi T, Itami J, Boku N. Risk factor analyses of severe cicatricial stricture
after chemoradiotherapy for stage II/III (T3) esophageal carcinoma. ASCO 2017 Gastrointestinal
Cancers Symposium, Jan. 19–21, 2017; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Kato K, Kojima T, Ito Y, Igaki H, Daiko H, Onozawa M, Hamamoto Y, Matsushita N, Nagashima K, Katano
S. Feasibility study of neo-chemoradiotherapy for stage IB/II/III esophageal squamous cell
carcinoma: A 4-year follow up. 2016 the Japanese Society of Medical Oncology Annual Meeting, Jul.
28–30, 2016; Kobe Internatinal Conference Center & Kobe Internatinal Exhibition Hall,
Kobe. [Abstract]
Suzuki W, Ohyanagi F, Yanai T, Hashimoto H, Takashima A, Nakao M, Nakayama T, Iwasa S, Nagashima K,
Yamamoto N. A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced
by cisplatin-based chemotherapy. 2016 the Japanese Society of Medical Oncology Annual Meeting, Jul.
28–30, 2016; Kobe Internatinal Conference Center & Kobe Internatinal Exhibition Hall,
Kobe.
Hashimoto H, Yanai T, Nagashima K, Okita NT, Horinouchi H, Takiguchi T, Ohyanagi F, Nakao M, Takeda
K, Nakayama T, Sakai H, Arai T, Minato K, Kogure Y, Harada D, Suzuki K, Boku N, Shimada Y, Iwasa S,
Yamamoto N. A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced
by highly emetogenic chemotherapy with cisplatin. 2016 ASCO Annual Meeting, Jun 3–7, 2016;
McCormick Place, Chicago, Illinois. (Poster, J Clin Oncol
2016; 34(suppl): abstr 10111) [Abstract]HOT
Ohba A, Takashima A, Nishiuchi T, Honma Y, Iwasa S, Okita N, Kato K, Hamaguchi T, Nagashima K, Boku
N. Second-line chemotherapy with paclitaxel for elderly patients with advanced gastric cancer. ASCO
2016 Gastrointestinal Cancers Symposium, Jan. 21–23, 2016; Moscone West Building, San
Francisco, CA. (Poster) [Abstract]
Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Yoshitaka Honma Y, Iwasa S, Okita N,
Takashima A, Kato K, Yamada Y, Katayama N, Narikazu Boku N, Hamaguchi T, Heike Y. Immune status at
pre-treatment impacts on progression-free survival of metastatic colorectal cancer patients treated
with first-line chemotherapy. 30th Annual Meeting and Associated Programs of the Society for
Immunotherapy of Cancer (SITC 2015), Nov. 4–8, 2015; Gaylord National Hotel & Convention
Center, National Harbor, Maryland. (Poster) [Abstract]
Sasaki Y, Akasu T, Saito N, Kojima H, Matsuda K, Nakamori S, Komori K, Amagai K, Yamaguchi T,
Nagashima K, Okita N, Yamada Y. Impact of KRAS/NRAS mutation status on the outcomes of patients with
stage III colorectal cancer: Correlative study in NSAS-CC/RC. The 18th ECCO - 40th ESMO European
Cancer Congress, Sep. 25–29, 2015; Messe Wien Exhibition & Congress Centre, Vienna,
Austria. (Poster) [Abstract]
Shoji H, Heike Y, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Ito A, Honma Y, Iwasa S,
Okita N, Takashima A, Kato K, Yamada Y, Boku N, Hamaguchi T. Association between the peripheral
immune status of granulocytic myeloid-derived suppressor cells and progression-free survival
chemotherapy. The 18th ECCO - 40th ESMO European Cancer Congress, Sep. 25–29, 2015; Messe Wien
Exhibition & Congress Centre, Vienna, Austria. (Poster) [Abstract]
Tada K, Shoji H, Kitano S, Nishimura T, Shimada Y, Nagashima K, Ito A, Honma Y, Iwasa S, Okita M,
Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T. Identification of an
immunological prognostic factor for metastatic colorectal cancer patients treated with first-line
oxaliplatin-based chemotherapy. The 18th ECCO - 40th ESMO European Cancer Congress, Sep.
25–29, 2015; Messe Wien Exhibition & Congress Centre, Vienna, Austria. (Poster) [Abstract]
Honma Y, Terauchi T, Tateishi U, Kano D, Nagashima K, Okita NT, Takashima A, Iwasa S, Kato K,
Hamaguchi T, Shimada Y, Boku N, Yamada Y. Imaging peritoneal metastasis of gastric cancer with
PET/CT and the radiotracer 18F-fluorothymidine (18F-FLT): Proof-of-concept
study. 2015 ASCO Annual Meeting, May 29–Jun. 2, 2015; McCormick Place, Chicago, Illinois.
(Poster discussion session) [Abstract]
Hirashima Y, Hanaoka T, Watanabe K, Nagashima K, Inagaki T, Nishikawa K, Hisamatsu Y, Morinaga R,
Otsu S, Kumamoto T, Shirao K. A prospective study to evaluate the usefulness of the clanging tuning
fork test and the nerve conduction velocity test for oxaliplatin-induced peripheral neuropathy. ASCO
2015 Gastrointestinal Cancers Symposium, Jan. 15–17, 2015; Moscone West Building, San
Francisco, CA. (Poster) [Abstract]
Yuda S, Kato K, Sasaki Y, Takahashi N, Shoji H, Takashima A, Okita NT, Honma Y, Iwasa S, Hamaguchi
T, Yamada Y, Nagashima K, Boku N. Risks of severe adverse events of docetaxel, cisplatin, and
5-fluorouracil (DCF) combination chemotherapy of esophageal cancer. ASCO 2015 Gastrointestinal
Cancers Symposium, Jan. 15–17, 2015; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Kubo A, Yamada Y, Takahashi N, Nagashima K, Hashimoto H, Iwasa S, Honma Y, Okita N, Takashima A,
Kato K, Hamaguchi T, Hayashi Y, Shimada Y. Serum epiregulin is associated with prognosis and skin
toxicity on anti-EGFR antibody treatment in KRAS wild-type mCRC. The 73rd Annual Meeting of the
Japanese Cancer Association, Sep. 25–27, 2014; Pacifico Yokohama, Kanagawa. (Poster)
Kubo E, Kato K, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Shimada Y, Ito Y, Itami J, Nagashima K.
Comparison of the long-term toxicities with two different chemoradiotherapy for esophageal squamous
cell carcinoma. The 12th Annual Meeting of Japanese Society of Medical Oncology, Jul. 17–19,
2014; Fukuoka.
Takahashi S, Ishiwada N, Hishiki H, Nagasawa K, Chang B, Nagashima K. Serotype distribution and drug
resistance of streptococcuspneumoniae isolated from children with community acquired pneumonia in
Japan. 13th International Congress on Pediatric Pulmonology, Jun. 26–29, 2014; Bruges,
Belgium. (Poster) [Abstract]
Iwasa S, Hamaguchi T, Nagashima K, Goto M, Okazaki S, Sasaki Y, Nagai Y, Asami C, Shimada Y.
Multicenter phase II study of combination therapy with oral S-1 plus cisplatin in elderly patients
with advanced gastric cancer. ESMO 16th World Congress on Gastrointestinal Cancer, Jun. 25–28,
2014; Barcelona, Spain. (Poster) [Abstract]
Kato K, Hashimoto J, Ito Y, Nagashima K, Kojima T, Daiko H, Akimoto T, Hamamoto Y, Matsushita H,
Katano S, Hara H, Tanaka Y, Saito Y, Igaki H. Phase II study of neoadjuvant chemoradiotherapy with
cisplatin plus 5-fluorouracil and elective nodal irradiation for stage II/III esophageal squamous
cell carcinoma: A 2-year follow up. ASCO 2014 Gastrointestinal Cancers Symposium, Jan. 16–18,
2014; The Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Goto A, Yamada Y, Iwasa S, Nagashima K, Yamaguchi T, Ichikawa Y, Yasui H, Kato K, Okita NT, Shimada
Y. S-1 and irinotecan versus 5-fluorouracil and leucovorin plus oxaliplatin with or without
bevacizumab in metastatic colorectal cancer: A pooled analysis of 4 phase II studies. The 17th ECCO,
38th ESMO, 32nd ESTRO, European Cancer Congress. Sep. 27–Oct. 1, 2013; Amsterdam. (Poster) [Abstract]
Hirashima Y, Hanaoka T, Watanabe K, Nagashima K, Nishikawa K, Morinaga R, Otsu S, Kumamoto T, Shirao
K. A prospective study to evaluate the usefulness of neurological test for oxaliplatin-induced
peripheral neuropathy. The 11th Annual Meeting of Japanese Society of Medical Oncology, Aug.
29–31, 2013; Tohoku University Centennial Hall, Sendai, Miyagi.
Kato K, Nakajima T, Ito Y, Katada C, Ishiyama H, Tokunaga S, Tanaka M, Hironaka S, Hashimoto T, Ura
T, Kodaira T, Yoshimura K, Nagashima K, Ishikura S. Phase II study of concurrent chemoradiotherapy
with elective nodal irradiation for stage II-III esophageal carcinoma, modified RTOG regimen. The
9th Annual Meeting of Japanese Society of Medical Oncology, Jul. 21–23, 2011; Pacifico
Yokohama, Yokohama, Kanagawa.
Okita NT, Kato K, Tokunaga S, Esaki T, Baba E, Takiuchi H, Mizunuma N, Kato T, Inaba Y, Kanemitsu Y,
Yasui H, Fuse N, Hamaguchi T, Yamada Y, Shimada Y, Nagashima K. Dose Initial tumor size affect
bevacizumab efficay in 1st-line FOLFOX treatment for metastatic CRC? The 9th Annual Meeting of the
Japanese Society of Medical Oncology, Jul. 21–23, 2011; Pacifico Yokohama, Yokohama, Kanagawa.
(Poster)
Hirashima Y, Yamada Y, Tateishi U, Kato K, Miyake M, Horita Y, Akiyoshi K, Nagashima K, Nakajima TE,
Hamaguchi T, Shimada Y, Shirao K. New analysis of the hypertension mechanism in bevacizumab-treated
patients using 3-Tesla dynamic contrast-enhanced magnetic resonance imaging. ASCO 2011
Gastrointestinal Cancers Symposium, Jan. 20–22, 2011; The Moscone West Building, San
Francisco, CA. (Poster) [Abstract]
Akiyoshi K, Yamada Y, Hirashima Y, Horita Y, Kato K, Nagashima K, Nakajima TE, Hamaguchi T, Shimada
Y. Phase II trial of the second-line 5-fluorouracil ℓ-leucovorin/irinotecan (FOLFIRI) and
bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial. ASCO 2010
Gastrointestinal Cancers Symposium, Jan. 22–24, 2010; The Orlando World Center Marriott,
Orlando, Florida. (Poster)
Yoshida H, Okita NT, Esaki T, Baba E, Sakai D, Tokunaga S, Takiuchi H, Mizunuma N, Nagashima K, Kato
K. Phase II study of the "stop and go" modified FOLFOX6 regimen with bevacizumab for first-line
patients with metastatic colorectal cancer. ASCO 2010 Gastrointestinal Cancers Symposium, Jan.
22–24, 2010; The Orlando World Center Marriott, Orlando, Florida. (Poster)